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ABSTRACT 
The incidence of melanoma is increasing world-wide, and Australia has the highest rate of 
melanoma in the world.  Hence there is an urgent need for safe and effective treatments.  The 
aim of this thesis was to elucidate our understanding of the role that the complement system, 
in particular the complement anaphylatoxins C3a and C5a, plays in tumour development and 
growth.  
Given the mounting evidence for a role for the C5a receptor (C5aR1) in the growth of other 
tumour types, Chapter 3 explored the role of C5aR signalling in a murine model of 
melanoma.  Immunostaining revealed that B16 murine melanoma cells expressed both 
receptors for C5a (C5aR1 and C5aR2).  Although C5aR1 was capable of ERK activation in 
response to recombinant mouse C5a, there was no effect on cell proliferation or migration.  
Melanoma growth was significantly retarded in C5aR1-deficient (C5aR1-/-) mice, and the 
growth of established melanomas was inhibited by treatment of wild-type mice with a C5aR1 
antagonist (C5aR1A), thus suggesting the potential of C5aR1 as a therapeutic target for 
melanoma.  In accord with the premise that C5aR2 acts as a modulator of C5aR1, tumour 
growth was enhanced in mice lacking C5aR2.   
Given that the growth of C5aR-expressing tumour cells was retarded in C5aR1-/- mice, we 
hypothesised that the protective effect of C5aR1 inhibition could be due to changes in the 
immune response.  This was supported by FACS analysis which showed a significant 
increase in tumour infiltrating leukocytes in C5aR1-/- mice.  Myeloid derived suppressor 
cells (MDSC) were significantly reduced in both C5aR1-/- and C5aR1A-treated wild-type 
mice, whereas tumour-infiltrating CD3+ and CD4+ T lymphocytes were increased.  Tumour 
infiltrating leukocyte populations in C5aR2-/- mice were not significantly different from 
those of their wild-type counterparts.  Tumour tissue from C5aR1-deficient mice also showed 
significantly lower levels of chemokines CCL2, CCL4 and CCL5, all known to regulate the 
movement of MDSC and maintain their immunosuppressive activity. 
Chapter 4 investigated whether C3aR, like the C5aRs, also plays a role in regulating tumour 
growth.  Like C5aRs, C3aR was detected at low levels on B16 melanoma cells in vitro and in 
vivo.  Moreover these cells responded to C3a, activating ERK and AKT signalling pathways 
and enhancing cell migration.  The tumour-promoting activity of C3aR signalling was 
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demonstrated by in vivo studies which showed that B16 melanomas were retarded in C3aR-
deficient (C3aR-/-) mice.  The growth of established melanomas was arrested by treatment 
with C3aR antagonist (C3aRA), suggesting that C3aR, like C5aR1, may be a therapeutic 
target for melanoma.  Further, the anti-tumour effect observed in C3aR-/- mice was not 
augmented by treatment with C5aR1A, implying that in this model the tumour-promoting 
effects of C3a are at least as potent as those of C5a.   
The demonstration that growth of C3aR-expressing B16 cells is retarded in C3aR-deficient 
mice suggested that, as for C5aR, the tumour-promoting effects of C3a-C3aR signalling are 
via the host immune system.  This was supported by FACS analysis showing alterations in 
tumour infiltrating leukocyte populations in the absence C3aR signalling.  Whereas C5aR 
was shown to act via induction of MDSC and inhibition of T lymphocytes, C3aR deficiency 
lead to increased neutrophils, monocytes and CD4+ T-cell subsets (Th1, Th2 and Th17) 
within the tumour.   
The increase in tumour infiltrating neutrophils in C3aR-/- and C3aRA-treated mice is in 
accord with recent research demonstrating a role for C3a-C3aR signalling in the retention of 
neutrophils in the bone marrow (Wu et al., 2013).  The central role of neutrophils in the 
tumour inhibitory response observed in C3aR-/- mice was confirmed by neutrophil depletion 
experiments which significantly reversed the anti-tumour effects, and returned CD4+ T 
lymphocyte populations to wild-type levels.  The association of C3aR-deficiency with 
increased tumour infiltrating CD4+ cells suggests the existence of a positive feedback loop 
whereby the secretion of chemokines and cytokines by neutrophils sequestered to the tumour 
microenvironment promotes CD4+ recruitment and expansion; cytokines produced by CD4+ 
cells may in turn favour neutrophil recruitment and survival.  Similar to previous studies 
which showed an up-regulation of M1-associated cytokines/chemokines in anti-tumour 
myeloid cell populations, we show up-regulation of IL-1β and CCL5 in plasma and tumour 
tissue (respectively) from C3aR-/- mice.  Finally, we showed that C3aR deficiency is also 
protective in murine BRAFV600E mutant melanoma and colon cancer models, suggesting the 
broader potential of C3aR as a therapeutic target for cancer.   
Collectively, the results presented in this thesis demonstrate the key role of complement 
components C3a and C5a in regulating the anti-tumour immune response to melanoma.  They 
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not only confirm previous reports of a tumour-promoting role for C5aR, but identify a 
hitherto unknown role for C3a in regulating tumour growth.  Whereas C5a appears to exert its 
effects via induction of MDSC and Tregs, C3a mediates its effects via regulation of 
neutrophil and CD4+ T lymphocyte populations.  Thus by altering the tumour inflammatory 
milieu, inhibition of either C5aR or C3aR tips the balance towards an effective anti-tumour 
response.  
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1.1 GENERAL INTRODUCTION 
Melanoma is the most dangerous type of skin cancer.  It accounts for less than 5% of skin 
cancer cases, but is responsible for the majority of skin cancer deaths (Kuphal and 
Bosserhoff, 2009).  Australia has the highest rate of melanoma in the world, and in the last 30 
years, the incidence has doubled (Garbe and Leiter, 2009).  Melanoma is able to spread or 
metastasise to skin, subcutaneous tissues, distant lymph nodes, lung, liver and brain 
(Silberman, 1987).  There are several options available for treating melanoma, including 
surgery, immunotherapy (Alexandrescu et al., 2010), radiation therapy and chemotherapy, 
depending on the extent of the disease (Naylor et al., 2006).  However despite recent 
improvements in therapy, advanced melanoma remains poorly responsive to systemic therapy 
(Hegde et al., 2011), with a 3 year survival rate of less than 15% for metastatic disease 
(Eggermont et al., 2014). While numerous studies have investigated immunotherapeutic 
approaches (Weber, 2011; Yao et al., 2011), to date these have met with limited success, 
extending survival rate by only a few months (Leach et al., 1996; Pandolfi et al., 2008; 
Pardoll, 2012). The present project investigates the role of inflammatory mediators, the 
complement components C3a and C5a, in melanoma growth.  
1.2 MELANOMA 
Melanoma is a malignant tumour of melanocytes, and is the most serious type of skin cancer. 
Melanocytes are pigment-producing (melanin) cells responsible for skin colour and 
protecting the deeper layer of the skin from harmful ultraviolet rays (Noonan et al., 2001). 
Melanocytes originate from multipotent melanocyte stem cells (MSCs) in the neural crest 
through the process of melanogenesis (Erickson and Reedy, 1998). During embryonic 
development, multipotent glial-melanocyte progenitors are generated in the neural crest, and 
through Wnt signalling produce melanoblasts that develop into melanocytes (Dupin et al., 
2000; Ikeya et al., 1997).  
1.2.1 Epidemiology 
Melanoma accounts for less than 5% of skin cancer cases, but is responsible for the majority 
of skin cancer deaths (Kuphal and Bosserhoff, 2009). According to the World Health 
Organisation (WHO) the world wide incidence of melanoma is increasing at a faster rate than 
any other cancer type with approximately 53,000 deaths annually (World Health Organisation 
2014) Queensland has the highest rate of melanoma in the world, and in the last 30 years, the 
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incidence has almost doubled in Australia, from 26.7 per 100,000 in 1982 to 48.8 per 100,000 
in 2014 (Australian Institute of Health and Welfare 2014).  Melanoma is able to metastasise 
to skin, subcutaneous tissues, distant lymph nodes, lung, liver and brain (Silberman, 1987). 
Melanoma arises as the result of interactions between environmental, genetic and host 
factors. 
1.2.2 Environmental factors 
Prolonged exposure to UV rays causes melanocytes to grow abnormally and (in some cases) 
develop into cancerous cells (melanoma). UV radiation from the sun causes sunburn, skin 
damage and sometimes cancer. There are three types of ultraviolet rays: UV-A, UV-B and 
UV-C.  UV-A is the most common and most damaging form of radiation, since it is constant 
throughout the seasons and in contrast to other rays, penetrates the skin layers more deeply, 
damaging skin connective tissue (Cascinelli, 1989). Exposure to UV-A can cause premature 
ageing, sunburn and increased cancer risk. UV-B rays are stronger than UV-A but they are 
more intense during summer, at high altitudes and closer to the equator. Most UV-B rays are 
absorbed by the ozone layer around the earth, and therefore they are less of a concern. 
However, the remaining UV-B that reaches the earth also causes ageing, sunburn and loss of 
skin elasticity. Finally the most dangerous and strongest rays are UV-C, but these are usually 
filtered out by the ozone layer and generally do not reach the earth (Sugiyama et al., 1985).  
1.2.3 Genetic mutations 
The understanding of molecular pathways and mutations from which melanomas originate 
are keys to histopathologic diagnosis and targeted mutation-specific treatments. Large scale 
sequencing of components of the ERK pathway revealed a high frequency mutation in BRAF 
as the most common genetic lesion in human melanoma (Davies et al., 2002), with 44% of 
melanomas containing mutations in BRAF, 21% NRAS, 2% KRAS and 1% HRAS (Curtin et 
al., 2006). The consequence of these mutations is constitutive activation of ERK in melanoma 
cells.  Over 90% of BRAF mutations occurring in melanoma are due to a glutamic acid for 
valine substitution at position 600 (V600E) which results in a 500-fold increase in BRAF 
activation (Davies et al., 2002).  
c-KIT (CD117) is a receptor tyrosine kinase which in humans is  encoded by the KIT gene 
and upon binding to its stem cell ligand induces downstream signalling pathways regulating 
cell growth and differentiation (Andre et al., 1997). Point mutations along the KIT gene (in 
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exons 11, 13 and 17) have been found to occur in 20% of acral, mucosal and melanoma 
patients (Beadling et al., 2008; Curtin et al., 2006; Woodman et al., 2009).  
The Cancer Genome Atlas (TCGA) project, begun in 2005, uses a bioinformatics approach to 
catalogue genetic mutations responsible for cancer. TCGA examination of genomic 
alterations in primary and/or metastatic melanoma from 331 patients has confirmed four 
genomic subtypes; BRAF, RAS, NF1 and Triple-WT with considerable expression of immune 
infiltration markers among the subtypes which is correlated with overall patients survival and 
potential application for immunotherapy (Cancer Genome Atlas, 2015). This study further 
illustrated that 76% of primary and 84% of metastatic melanoma samples had a UV signature 
(ie a high level of C>T and CC>TT transitions). Interestingly samples enriched for genes 
associated with lymphocyte infiltration were linked to improved patient survival. Other 
studies have an mTOR point mutation in the P13K-AKT-mTOR signalling pathway which is 
harboured by 6.1 % of melanomas (Grabiner et al., 2014).  Upregulation and/or variation in 
the expression of the DNA cytosine deaminase APOBEC3B (an enzyme that provides innate 
immunity against DNA-based parasitic elements) has also been reported in melanoma (Burns 
et al., 2013b). Together these findings broaden our understanding of the genomic landscape 
of cancers and have implications for cancer diagnosis and targeted therapy.  
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1.2.4 Staging of melanoma 
Based on analysis of data from 17,600 patients, the Melanoma Staging Database was used by 
The American Joint Committee on Cancer (AJCC) to identify a number of factors that 
determine melanoma prognosis and staging, such as presence or absence of tumour 
ulceration, mitotic/proliferation rate, tumour burden and thickness of the melanoma (Balch et 
al., 2009). These are summarised in Table 1.1. 







Stage I Localised melanoma, no distant 
metastasis, thickness <1.5 mm 
10 years 97% 
IA   93% 
IB    
Stage II Localised melanoma   
IIA Thickness 1.5-4.0mm   
IIB Thickness >4.0 mm   
IIC  10 years 39% 
Stage III Regional metastatic melanoma 5 years 39% 
IIIA  5 years 78% 
IIIB  5 years 59% 
IIIC  5 years 40% 
Stage IV Distant metastatic melanoma   
M1a Metastasis in the skin and distant lymph 
nodes and normal LDH level. Good 
prognosis 
1 year 62% 
M1b Metastasis to the skin and lung with 
normal LDH level. Intermediate prognosis 
1 year 53% 
M1c Metastasis to other locations with elevated 
LDH level. Poor prognosis 
1 year 33% 
  
   6 
 
1.2.5 Treatment 
The most effective treatment option for melanoma is surgical intervention, but only for early 
stage disease which has a greater than 90% 10 year survival rate. However, as the disease 
progresses, there is an increased risk of recurrence and the survival rate drops significantly.  
Treatment for metastatic melanoma remains poor with a 5 year survival rate of less than 15% 
(Balch et al., 2001; Hegde et al., 2011). Despite numerous attempts at immunotherapy for 
melanoma (Weber, 2011; Yao et al., 2011), these have been largely unsuccessful (Pandolfi et 
al., 2008). However recent clinical trials have demonstrated potent clinical efficacy for 
immunotherapeutic antibodies which inhibit immune checkpoints for T cell activation, 
cytotoxic T-lymphocyte-associated protein 4 (CTL-4; Hodi et al., 2010; Robert et al., 2011) 
and programmed cell death (PD)-1 (Brahmer et al., 2012; Leach et al., 1996; Topalian et al., 
2012a; Topalian et al., 2012b). Pembrolizumab and nivolumab block programmed cell death 
(PD-1) receptor from binding to its ligand PD-L1 (Brahmer et al., 2012; Hamid et al., 2013; 
Robert et al., 2014; Robert et al., 2011). However the therapeutic benefits are short-lived, and 
increase overall survival by only a few months (Sanderson et al., 2005; Yang et al., 2005).  
The identification of targetable somatic mutations in genes such as BRAF (McArthur and 
Ribas, 2013) and NRAS (Jakob et al., 2012) has led to promising oncogene-targeted 
therapeutic strategies which  improve survival of patients with advanced melanoma. The 
BRAF inhibitor antibodies interrupt signalling through the MAPK pathway, altering cell 
proliferation and survival and inducing apoptosis of melanoma cells.  Clinical studies have 
reported that anti-BRAF antibodies vemurafenib (formerly PLX4032) and debrafenib 
(formerly GSK2118436) induce a high frequency of tumour regression among metastatic 
melanoma patients with BRAF V600E positive mutations, and lead to improved overall 
survival (Falchook et al., 2012; Flaherty et al., 2010; Sosman et al., 2012). However, in the 
majority of patients disease progression is resumed after the initial BRAF inhibitor-based 
therapy due to the tumour rapidly developing resistance to these antibodies. This occurs 
because of reactivation of the MAPK pathway, up-regulation of the ser/thr MAP kinase 
kinase kinase (MAP3K8) (Johannessen et al., 2010; Nazarian et al., 2010; Poulikakos et al., 
2011; Shi et al., 2012a; Shi et al., 2012b; Wagle et al., 2011) or activation of alternate 
survival pathways (Nazarian et al., 2010; Straussman et al., 2012; Villanueva et al., 2010).  
The discovery of genetic aberrations in the c-KIT gene in some melanoma patients has 
identified it as an additional therapeutic target for metastatic melanoma. Imatinib is an oral 
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tyrosine kinase inhibitor that has demonstrated increased survival in patients harbouring c-
KIT mutation or amplification (Carvajal et al., 2011; Guo et al., 2011). Dasatinib, another 
tyrosine kinase inhibitor, has been observed to inhibit the proliferation of melanoma cell lines 
(Woodman et al., 2009) and improve response rates in melanoma patients (Kalinsky et al., 
2012). Ongoing clinical trials are investigating the potential of dasatinib as an individual 
therapy or in combination with immunotherapy.  
Further understanding of the role of the immune system in tumour development and growth, 
and the interaction with other clinical strategies, will lead to improved treatments for 
melanoma and other cancers.  
1.3 IMMUNE SURVEILLANCE 
1.3.1 The role of the immune response in tumour development and growth 
There is overwhelming evidence that the immune system is capable of recognising tumours 
as ‘altered self’. However the role of the immune system in tumour growth has long been 
debated, with evidence for both anti-tumour and tumour-promoting effects (Dunn et al., 
2002). The concept of tumour ‘immune surveillance’ refers to recognition and, in most cases, 
destruction of cancer precursors before tumours can develop (Burnet, 1970).  
The theory that the immune system is capable of recognising and eliminating cancer cells was 
first proposed by Ehrlich in 1909. However, evidence that the immune system can be induced 
to mount an effective anti-tumour response was provided even before this by Coley (1891) 
who demonstrated that administration of bacterial toxins induced a successful anti-tumour 
immune response to sarcomas. This idea is supported by studies showing that 
immunodeficient mice have increased tumour incidence compared to wild-type mice (Street 
et al., 2001; Stutman, 1975; Trainin et al., 1967), and similarly that immunosuppressed 
patients have a higher incidence of some tumour types than healthy controls (Koebel et al., 
2007). Historically, the presence of leukocytes in and around tumour tissues was thought to 
indicate an attempt by the host to eradicate the tumour, and the infiltration of pro-
inflammatory T-lymphocytes has been associated with an improved prognosis in a range of 
cancers, including ovarian, colorectal, and breast cancers (Kryczek et al., 2009; Prestwich et 
al., 2008).  
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Despite the evidence that the immune system can recognise tumour cells as foreign and 
mount a response against them, these defence mechanisms sometimes fail. There are a 
number of ways that tumours are thought to evade detection by the immune system. For 
example, tumours can either reduce or modify their expression of tumour-associated antigens, 
so that immune recognition is reduced (Bai et al., 2003). Moreover, most tumour antigens are 
poorly immunogenic and elicit weak immune responses, thus preventing an effective anti-
tumour response (Whiteside, 2008). Tumour cells produce a variety of soluble factors that 
suppress the immune response against them (Janke et al., 2000). These include 
immunoinhibitory cytokines such as transforming growth factor (TGF)-𝛽𝛽 and interleukin 
(IL)-10 (Prestwich et al., 2008; Quatromoni and Eruslanov, 2012) which inhibit effective 
immune responses or induce tumour-promoting responses in cancer patients (Janke et al., 
2000; Whiteside, 2008). Other soluble tumour products such as chemokines recruit 
Figure 1.1 The three phases of immunoediting: ‘elimination’, ‘equilibrium’ and 
‘escape’ (Chikamatsu*, 2013). 1. Immune surveillance leads to successful elimination 
of the cancer; 2. tumor cells that survive the immune surveillance process are in 
equilibrium with the host immune system; 3. tumor cells escape detection and 
elimination by the host immune system. 
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immunosuppressive inflammatory cells to inhibit the development of an effective adaptive 
immune response (Shields et al., 2010).  This includes tumour-associated macrophages 
(TAM) or myeloid-derived suppressive cells (MDSC) and their secreted cytokines IL-6, 
tumour necrosis factor (TNF) and IL-1β, all of which have been shown to promote tumour 
development (Gabrilovich and Nagaraj, 2009; Movahedi et al., 2010). CD4+ T lymphocyte 
subsets (particularly T helper (Th17) and CD25+ Foxp3+ regulatory (Treg) lymphocytes) have 
also been associated with poor prognosis and decreased survival of patients with breast and 
renal carcinomas (DeNardo et al., 2008; Ruffell et al., 2010; Siddiqui et al., 2007). 
The ‘immune surveillance’ theory was formulated by Burnet (1970) who proposed that 
immune cells identify antigens expressed by tumour cells, and then eliminate them before a 
detectable tumour develops. More recently this theory has been updated as the 
‘immunoediting’ hypothesis which describes three phases: 1) ‘immunosurveillance’ which 
involves active eradication of immunogenic tumour cells; 2) an ‘equilibrium’ phase which 
occurs if the tumour is not completely eliminated but is prevented from unrestrained growth; 
3) an ‘escape’ phase in which tumour cell variants are selected that avoid or suppress the 
immune system (Bui and Schreiber, 2007; Swann and Smyth, 2007) (Figure 1). 
1.4 OVERVIEW OF THE IMMUNE SYSTEM 
The immune system can be divided into innate and adaptive (or acquired) responses that are 
mediated by distinct cell types (Roitt and Delves, 2001). Together these cells defend the host 
against invading pathogens and damaged cells by recognising and eliminating them, and 
restoring tissue homeostasis. 
1.4.1 The innate immune system  
The innate immune system is the first line of defence, responding rapidly to infection or 
tissue injury. It provides an immediate response to injurious stimuli but does not confer 
memory or lasting protective immunity to the host. It is mediated by a number of cell types 
including macrophages, mast cells, dendritic cells, natural killer (NK) cells, and granulocytes 
(polymorphonuclear neutrophils, basophils and eosinophils) which are recruited to the site of 
infection (Roitt and Delves, 2001).  
Innate immune cells such as macrophages and mast cells continuously patrol their 
microenvironment for distress signals and are pivotal in initiating inflammation. Upon 
detecting distress signals, these cells immediately release soluble mediators such as 
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chemokines, cytokines and reactive oxygen species which activate other immune cells and 
attract them to the site of injury (Whiteside, 1999). This includes phagocytic cells which 
engulf pathogens and infected or injured cells.  Professional phagocytes include neutrophils, 
monocytes, macrophages, mast cells and dendritic cells, all of which express receptors such 
as scavenger receptors, toll-like receptors (TLRs) and pattern recognition (PRRs) capable of 
recognising foreign objects, damaged cells or danger signals not found in healthy tissues 
(Erwig and Henson, 2008; Hajishengallis and Lambris, 2011).  
1.4.1.1 Neutrophils 
Neutrophils, also called polymorphonuclear neutrophils (PMNs), constitute the majority of 
circulating leukocytes (10-25% in mice and 50-70% in humans) (Doeing et al., 2003; Mestas 
and Hughes, 2004).  Daily production of neutrophils can reach up to 2x1011 cells 
(Borregaard, 2010). Circulating neutrophils have a short half-life of approximately 12.5 hours 
and 5.4 days in mice and humans, respectively under steady state conditions (Galli et al., 
2011; Pillay et al., 2010). However, during inflammation, the survival of activated 
neutrophils increases by several fold, ensuring the recruitment of neutrophils to the site of 
injury/inflammation (Colotta et al., 1992; Kim et al., 2011; Summers et al., 2010).  
Neutrophils develop in the bone marrow from myeloid precursors via a process called 
granulopoiesis. The principal regulator of this process is granulocyte colony stimulating 
factor (G-CSF; CSF-3) whose effects include progenitor cell commitment to the myeloid 
lineage, proliferation of granulocytic precursors, and release of mature cells from the bone 
marrow (Summers et al., 2010). G-CSF is produced in response to the pro-inflammatory 
cytokine IL-17A which is synthesized by specialized T lymphocytes (Th17) and released in 
response to IL-23 produced by tissue macrophages and dendritic cells (DC) (Ley et al., 
2006). The bone marrow serves as a reservoir for neutrophils, such that less than 2% of 
mature neutrophils are in the circulation under basal conditions (Semerad et al., 2002). 
Neutrophil retention and release from the bone marrow is orchestrated by chemokines: 
stromal derived factor-1 (SDF-1; CXCL12) binding to its CXC chemokine receptor 4 
(CXCR4) results in bone marrow neutrophil retention whereas neutrophil release is mediated 
by CXCR2 produced by bone marrow stromal cells (Eash et al., 2010; Martin et al., 2003).  
Upon appropriate stimulation, circulating neutrophils adhere via specific receptors to ligands 
expressed by endothelial cells lining the blood vessel walls, and migrate between these cells. 
   11 
 
Once within the tissue, neutrophils are rapidly recruited by chemokines such as IL-8 (CXCL8 
in humans, CXCL1/KC in mice) to the site of inflammation, where they eradicate invading 
pathogens via phagocytosis, release preformed granular enzymes and proteins, and produce 
reactive oxygen species. Upon resolution of the inflammatory stimulus, neutrophils undergo 
apoptosis and are cleared by macrophages; this in turn leads to down-regulation of IL-23 and 
reduction of G-CSF release (Borregaard, 2010; Christopher and Link, 2007; Stark et al., 
2005). Senescent neutrophils have also been shown to home back to the bone marrow 
(Casanova-Acebes et al., 2013).  
For decades, neutrophils have been considered the first responders in acute inflammatory 
conditions such as lung injury, and are indispensable for protecting from bacterial and fungal 
pathogens (Grommes and Soehnlein, 2011; Kolaczkowska and Kubes, 2013; Moraes et al., 
2006; Williams and Chambers, 2014). However, there is compelling evidence to suggest that 
neutrophils are more complex cells capable of a vast array of specialised functions. The 
sustained influx of neutrophils has been observed in inflammatory conditions such as 
cardiovascular disease, rheumatoid arthritis and chronic obstructive pulmonary disease. Their 
role in chronic diseases and cancers has just begun to be recognised. The recruitment of 
neutrophils into the inflammatory site is mediated by chemokines, complement fragment 
C5a, platelet activating factor and lipid mediators. Upon activation, neutrophils release a 
range of chemokines as well as toxic contents, such as reactive oxygen species (ROS) and the 
matrix metalloproteinase (MMP)-9 which contribute to tissue damage and remodelling by 
degrading extracellular matrix components (Christoffersson et al., 2012).  MMP-9 also 
regulates leukocytosis (Opdenakker et al., 1998) and activates bound growth factors such as 
vascular endothelial growth factor-A (VEGF-A), a key mediator of angiogenesis (Van den 
Steen et al., 2002). 
Neutrophils contribute to the regulation of inflammatory responses through production of 
large variety of cytokines and chemokines. Depending on the stimulatory factors, neutrophils 
can synthesise and release cytokines such as IL-1ß, TNFα, IL-6 and IL-12 (Dorhoi et al., 
2013). They also release a range of chemokines for neutrophils, monocytes, NK cells, DCs, 
helper T (Th1) and Th17 cells (Sadik et al., 2011), including IL-8/CXCL8, KC/CXCL1 
(Cassatella et al., 1992; Cassatella et al., 1995; Hachicha et al., 1995; Koch et al., 1995), 
macrophage inflammatory protein 2 (MIP-2α/CXCL2) (Huang et al., 1992; Xing et al., 
1994), MIP-1α/CCL3 and MIP-1ß/CCL4 (Lloyd and Oppenheim, 1992). Expression of these 
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cytokines/chemokines is triggered by activation of cytokine receptors, G protein coupled 
receptors such as complement receptors and pattern recognition receptors (PRR) such as TLR 
(Benelli et al., 2002; Cassatella, 1999).  Although recent findings have expanded the 
repertoire of neutrophil effector functions during acute inflammation, their role in cancer 
remains uncertain (Brandau et al., 2013).  Neutrophils have been shown to promote tumour 
progression, angiogenesis and metastatic seeding via the production of chemokines, 
cytokines, reactive oxygen species and matrix remodelling enzymes; they also contribute to 
MDSC populations which inhibit effector T cell responses (Gregory and Houghton, 2011). 
However, neutrophils can also possess anti-tumour properties (Souto et al., 2011) and are 
able to kill tumour cells directly or via regulation of adaptive immune responses (Eruslanov 
et al., 2014).  
1.4.1.2 Monocytes   
Monocytes originate from myelo-monocytic stem cells in primary lymphoid organs such as 
foetal liver and bone marrow (Robbins et al., 2012) and represent 4% and 10% respectively 
of total leukocytes.  Monocytes extravasate through the endothelial lining of blood vessels to 
seed tissues such as spleen and lung where they differentiate into macrophages or dendritic 
cells (Geissmann, 2010; van Furth and Cohn, 1968). In mice, splenic production of 
monocytes can be induced under inflammatory conditions (Fogg et al., 2006) and their 
survival, proliferation and differentiation completely depend on colony-stimulating factor 1 
(M-CSF; CSF-1) whose effects are mediated via the CSF-1 receptor (CSF-1R) (Cecchini et 
al., 1994; Dai et al., 2002). In humans, circulating blood monocytes can be divided into two 
main subsets: classical CD14+ and non-classical CD14low CD16+ monocytes (Passlick et al., 
1989). In response to a broad range of microbial cues, CD14+ monocytes secrete 
inflammatory cytokines and reactive oxygen species and phagocytose foreign particles.  
CD16+ monocytes are responsible for tissue surveillance and secrete TNF-α, IL-1ß and CCL3 
(Cros et al., 2010). In mice, monocyte subsets equivalent to human monocytes are Ly6Chi and 
Ly6Clow respectively (Cros et al., 2010; Ingersoll et al., 2010). In response to injury, Ly6Chi 
cells are recruited from the circulation to the site of inflammation where they differentiate 
into mononuclear phagocytes.  
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1.4.1.3 Macrophages  
Macrophages are a heterogeneous cell population, with different names according to their 
anatomical location and activation status (Gordon and Taylor, 2005).  They are distributed in 
all tissues throughout the body and play a critical role in host defence, inflammation and 
tissue remodelling by producing cytokines and phagocytosing foreign particles and cell 
debris. Macrophages recognize pathogens such as bacteria, fungi and viruses through a 
variety of cell surface and cytoplasmic receptors, including TLRs (Xu et al., 2007), NOD like 
receptors, RIG-I like receptor (RLRs), C-type lectin and scavenger receptors (Drickamer and 
Fadden, 2002; Janeway and Medzhitov, 2002; Zelensky and Gready, 2005). Upon binding of 
these receptors to pathogen, macrophages activate transcription factors such as signal 
transducer and activator of transcription (STATs), interferon-regulatory factor (IRFs), nuclear 
factor (NF)-κB, activator protein (AP) 1, peroxisome proliferator-activated receptor (PPAR)-
γ and cAMP-responsive element-binding protein (CREB), which interact with each other to 
induce expression of a wide range of cytokines including IL-1α and ß, IL-18, IL12, IL-6, IL-
23, α and ß interferons (IFN), IL-4, IL-10 and TGF-ß (Aderem and Ulevitch, 2000; Bopst et 
al., 1998; Elenkov and Chrousos, 2002; Lawrence and Natoli, 2011; Liu et al., 2014). 
Although  macrophages have the flexibility to switch their phenotype in response to micro-
environmental signals (Hagemann et al., 2008; Kawanishi et al., 2010; Mylonas et al., 2009; 
Rutschman et al., 2001), several macrophage subsets have been described based on specific 
gene expression profiles (Cros et al., 2010). Classically activated (M1) macrophages are 
induced by Th1 cytokines (IFNγ, TNFα) and granulocyte monocyte-colony stimulating factor 
(GM-CSF; CSF-2) to express pro-inflammatory mediators such as TNF-α, IL-1, IL-6, as well 
as reactive nitrogen and oxygen intermediates (Mantovani et al., 2007; Mills et al., 2000; 
Mosser and Edwards, 2008).  Alternatively activated (M2) macrophages are induced 
following exposure to Th2 cytokines (IL-4 or IL-13); these cells are characterised by 
expression of arginase1 (Arg1), chitinase 3-like 3 (Ym1), IL-10 and Mrc1 (CD206), and play 
a role in parasite infestation, tissue remodelling and tumour progression (Gordon and 
Martinez, 2010). 
Although all macrophages were originally thought to differentiate from monocytes, recent 
studies have shown that most tissue macrophages do not originate and are maintained 
independently from monocytes (Davies and Taylor, 2015; Hashimoto et al., 2013; Liu et al., 
2009; Schlitzer et al., 2013; Varol et al., 2009; Yona et al., 2013).  Rather, adult tissue 
   14 
 
macrophages are derived from embryonic precursors before birth, and are capable of self-
renewal (Hashimoto et al., 2013; Yona et al., 2013).  
1.4.1.4 Myeloid derived suppressor cells   
Myeloid derived suppressor cells (MDSC) are a heterogeneous group of myeloid progenitor 
and immature myeloid cells (IMC) which expand in states of inflammation and cancer to 
exert suppressive effects on host innate and adaptive  immune responses (Gabrilovich and 
Nagaraj, 2009; Gallina et al., 2006; Marx, 2008). In healthy conditions IMCs primarily reside 
in bone marrow and differentiate into mature granulocytes, macrophages or dendritic cells 
(Sawanobori et al., 2008). In pathological conditions including cancer, autoimmune disease, 
trauma and sepsis, IMCs are prevented from full differentiation into mature cells. MDSC 
have up-regulated expression of arginase1 (which depletes arginine from the tumour 
microenvironment and impairs T cell signal transduction and function), as well as inducible 
nitric oxide synthase (iNOS) and nitric oxide (NO) (which limit the efficacy of immune 
surveillance and inhibit the development of a specific adaptive immune response to the 
tumour). These cells possess mixed morphologies of granulocytes and monocytes but lack the 
cell surface markers expressed by them (Ostrand-Rosenberg and Sinha, 2009; Youn et al., 
2008). In addition, MDSCs promote tumour vascularization and angiogenesis by secreting 
high levels of soluble factors such as MMP-9 and VEGF (Balkwill et al., 2005; Torisu et al., 
2000; Yang et al., 2004). In mice MDSCs are characterised by expression of Gr-1 (Ly6C/G) 
and CD11b (also known as αM-integrin) (Kusmartsev et al., 2004), whereas in humans 
monocytic MDSC are characterized as HLA-DR-, CD11b+, CD33+ and CD14+ 
(CD11b + Ly6G-/Ly6C+ in mice) and granulocytic MDSC as HLA-DR-, CD11b+, CD33+, 
CD15+ (CD11b + Ly6G+/Ly6Clow in mice) (Wesolowski et al., 2013).  
1.4.1.5 Dendritic cells 
Dendritic cells (DC) are a specialized, but heterogeneous group of cells that reside mainly in 
the skin, the inner lining of the nose, the lungs, the stomach and the intestines.  DCs are bone 
marrow derived and, along with macrophages and monocytes, are part of the mononuclear 
phagocyte system (Auffray et al., 2009; Fogg et al., 2006; Steinman and Cohn, 1973). They 
are the most powerful professional antigen presenting cells (APC). Antigen presentation 
describes the process by which phagocytic cells (macrophages and dendritic cells) ‘present’ 
protein fragments of engulfed foreign materials on their surface for recognition by other cells 
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of the immune system (Steinman et al., 1974). DCs display antigens in the context of major 
histocompatibility complex (MHC) class I and II molecules, then migrate to the lymphoid 
tissues where they activate cytotoxic T cells as well as T helper cells to secrete cytokines to 
induce an immune response (Banchereau and Steinman, 1998; Hashimoto et al., 2011; 
Steinman, 2007). Although their phenotypic similarity to macrophages makes it difficult to 
evaluate their exact involvement in immune responses, they can be distinguished by their 
distinct ability to activate T cells in an antigen-dependent manner (Bogunovic et al., 2009; 
Ginhoux et al., 2009).  The maturation and migration of DCs to draining lymph nodes occur 
in response to cytokines such as TNF-α that are produced during tissue injury and exposure to 
microbial products (Banchereau and Steinman, 1998; Grewal and Flavell, 1998).  DCs have a 
major influence on Th1 and Th2 differentiation and tolerance induction (Moser and Murphy, 
2000) through activation of STAT4 and secretion of IL-12, IL-18 and IL-23 (Th1 response) 
(Macatonia et al., 1995) or IL-4 and IL-10 (Th2 polarization and generation of regulatory T 
cells) (Iwasaki and Kelsall, 1999; Kelleher et al., 1999).  
In the context of cancer, DCs play a key role in inducing and maintaining anti-tumour 
immunity, and hence prolong patient survival (Dieu-Nosjean et al., 2008; Iwamoto et al., 
2003; Ladanyi et al., 2007; Nakakubo et al., 2003). However, within the tumour environment 
their antigen-presenting function may be lost or inefficient. They may also be polarized into 
immunosuppressive/tolerogenic regulatory DCs by tumour production of cytokines such as 
IL-10, TGF-ß, VEGF, M-CSF and prostaglandin E2 (PGE2) (Preynat-Seauve et al., 2006; 
Zou, 2005). This may limit the activity of effector T cells, and lead to enhanced tumour 
growth and progression (Ma et al., 2014), as has been reported in colorectal cancer (Chaux et 
al., 1997) and melanoma (Ataera et al., 2011).   
1.4.1.6 Natural killer cells 
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system, comprising 
5-20% of human peripheral blood lymphocytes, and defined as CD3-CD56+ (Ferlazzo and 
Munz, 2004; Lanier et al., 1983). NK cells were first identified in 1975 as a distinct 
lymphocyte subset with the ability to kill tumour cells (Herberman et al., 1975a; Herberman 
et al., 1975b; Kiessling et al., 1975a; Kiessling et al., 1975b). NK cell activation and 
maturation can be triggered by IL-2, -12, -15, -21 and IFN-α/ß cytokines, thereby augmenting 
the cytolytic effect against tumour cells (Biron et al., 1999; Nutt et al., 2004; Smyth et al., 
2002). Upon activation, cytotoxic NK exocytose granules containing perforin and other 
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enzymes that lead to perforation of virus-infected and tumour cells (Lieberman, 2003; 
Voskoboinik et al., 2006). NK cells exert their effector mechanisms through coordinate 
expression of cytokines and chemokines such as IFN-γ, TNF, GM-CSF, MIP-1α and 
RANTES (regulated upon activation, normal T cell expressed and secreted; CCL5) leading to 
enhanced depletion of the implanted tumour (Biron et al., 1999; Dorner et al., 2004). NK cell-
derived IFN-γ is important for induction of the adaptive T cell response, hence these cells act 
as an interface between innate and adaptive immunity (Martin-Fontecha et al., 2004; Mocikat 
et al., 2003).   
1.4.2 The adaptive immune system  
The adaptive immune system provides the ability to recognise and eliminate a specific 
pathogen or other foreign agent.  It also provides long-term and specific immunity (‘immune 
memory’).  It is comprised of highly specialised cells: antibody-producing B lymphocytes 
which are responsible for ‘humoral’ responses and T lymphocytes (CD4+ and CD8+) which 
are responsible for ‘cell-mediated’ responses.  Lymphocytes arise from haemopoietic 
progenitors in the bone marrow. The thymus is the primary lymphoid organ where T cell 
development and maturation take place, whereas foetal liver and postnatal bone marrow are 
the sites for B cell development. These cells then migrate to the secondary lymphoid organs 
(spleen, lymph node and mucosa-associated lymphoid tissues) where they differentiate into 
effector cells (von Andrian and Mackay, 2000) which eradicate altered cells or pathogens, 
either by secretion of antigen-specific immunoglobulins (B lymphocytes) or direct cell-
mediated cytotoxicity (T lymphocytes) (Finch and Crimmins, 2004).  
1.4.2.1 B lymphocytes  
B lymphocytes are antibody-secreting cells responsible for the humoral arm of adaptive 
immunity, and comprise 7-10% of white blood cells in the circulation. Immature B cells 
migrate to the spleen and other secondary lymphoid tissues where they mature and 
differentiate into immunocompetent B cells. Each B cell expresses a unique immunoglobulin 
on its surface (the B cell receptor) which is capable of recognising and binding a single 
specific antigen. Upon binding its cognate antigen, the B cell requires an additional signal 
from a T helper cell before it can further differentiate into either a plasma B cell capable of 
secreting large amounts of antibody or a long-lived memory B cell (Fuchs and Matzinger, 
1992; Ho et al., 1994). B cells can be activated in either a T cell-independent or T cell-
dependent manner upon stimulation by foreign antigens. In T cell dependent responses, the 
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B-cell antigen receptor delivers antigen to intracellular sites where it is degraded and returned 
to the B-cell surface as a peptide complexed with an MHC class II molecule; this complex is 
recognized by antigen-specific armed helper T cells, which in turn stimulate B cell 
proliferation and differentiation into antibody-secreting plasma cells (Parker, 1993). 
Conversely some microbial antigens can activate B cells directly via TLR engagement in the 
absence of T-cell help, thus providing a rapid response to important pathogens (Vos et al., 
2000).   
Mizoguchi and colleagues (2002) introduced a new B cell subset known as 'regulatory B 
cells' which are identified by their IL-10 production. These cells alter the Th1/Th2 balance, 
by inhibiting T cell proliferation and cytokine production (IFN-γ and TNF-α) by Th1 cells.  
They also promote infiltration of CD4+CD25+Foxp3+ Treg cells and suppress Th17 cell 
differentiation. Based on these findings, it is likely that Breg cells play an important role in T-
cell plasticity.  These cells maintain tolerance by suppressing CD4+ T cell proliferation and 
production of pro-inflammatory cytokines IFN-γ (Carter et al., 2012) and IL-17 (Carter et al., 
2011), as well as promoting the infiltration of Treg cells (Liu et al., 2013). The role of B cells 
in cancer is complex and controversial, with evidence of both pro- and anti- tumour roles for 
B cells. For example, in the murine metastatic B16-F0 melanoma model, elimination of 
CD20+ expressing B cells increased lung tumour burden (Sorrentino et al., 2011) and optimal 
CD4+ and CD8+ anti-tumour responses have been shown to require B cells. Activated B cells 
(DiLillo et al., 2010) may also be highly cytotoxic towards tumour cells (Li et al., 2009; 
Sorrentino et al., 2011). Despite these findings, pro-tumour effects of B cells have also been 
reported.  For example, CD4+ helper T cell-dependent anti-tumour immunity (Qin et al., 
1998; Shah et al., 2005) and production of IFN- γ from CD8+ T cells and NK cells (Inoue et 
al., 2006) was enhanced in the absence of B cells, suggesting that B cell depletion may have 
therapeutic benefits.  
1.4.2.2 T lymphocytes  
Bone marrow-derived T lymphocytes migrate to the thymus for differentiation and acquire 
unique cell surface antigen-binding receptor, the T cell receptor (TCR), a heterodimer 
consisting of two different protein chains, TCRα and TCRß. In contrast to B cells, T cells 
recognise antigenic peptides in complex with MHC molecules (Moss et al., 1992) on the 
surface of APCs. Mature T lymphocytes express either CD4 or CD8 molecules and hence 
form two major sub-populations with helper/regulatory and cytotoxic activities (Stockwin et 
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al., 2000; von Andrian and Mackay, 2000). CD8+ cytotoxic T cells are capable of killing 
infected cells and tumour cells, whereas CD4+ cells act as ‘helpers’, secreting cytokines to 
facilitate different types of immune responses.  CD4+ cells can be further divided into Th1, 
Th2, Th17, Treg and follicular helper T subsets based on their distinct gene expression and 
regulation signatures. Activation of naive CD4+ cells is restricted to antigen presented by 
MHC II molecules on the surface of APCs such as dendritic cells (Stockwin et al., 2000). 
Specialised memory cells (either CD4+ or CD8+) maintain immune surveillance, so that on 
encountering antigen for a second time these cells initiate a more rapid and enhanced 
response (Roitt and Delves, 2001).  
CD8+ cytotoxic T lymphocytes (CTL) are a key component of adaptive immunity, circulating 
throughout the body and seeking out intracellular pathogens. CTL recognize antigens in the 
context of MHC class I molecule (expressed on all nucleated cells) (Sykulev et al., 1996) and 
effectively eliminate intracellular pathogens by direct lysis of antigen-bearing infected or 
malignant cells (Gullo et al., 2008; Walsh et al., 2008).  
CD8+ CTL activation, differentiation and proliferation require various cytokines including 
IL-2 (Frankenberger et al., 2005), IL-4 (Hiraoka et al., 2005), IL-7 (Bertagnolli and 
Herrmann, 1990), IL10 (Chen and Zlotnik, 1991), IL-12 (Pardoux et al., 1997), IL-15 (Kanai 
et al., 1996) and TNF-α (Kasahara et al., 2003). Among these, IL-2 has been shown to be a 
critical cytokine for inducing specific cytotoxicity (Gately et al., 1994; Ito et al., 2008; Leist 
et al., 1989; Lin et al., 2007). CTL play a well-defined role in restraining tumour 
development (Dunn et al., 2004).   
CD4+ T lymphocytes are classified on the basis of their cytokine expression profiles (Zhou et 
al., 2009). To date, five subsets of CD4+ T cells have been identified: Th1, Th2, (Mosmann et 
al., 1986) and Th17 cells (Ansel et al., 2003; Harrington et al., 2005) that target specific 
classes of pathogens, regulatory T cells (Tregs) (Wing and Sakaguchi, 2010) that are required 
to maintain self-tolerance, and follicular helper T cells (TFH) that provide help to B cells for 
antibody production (Ma et al., 2012).   
In response to infection with intracellular pathogens such as bacteria or viruses, specialized 
dendritic cells present antigen to uncommitted naïve T cells and, with the aid of cytokines IL-
12 and IL-2, induce the differentiation of CD4+ Th1 cells.  Th1 cells are characterised by the 
production of cytokines such as IFN-γ, TNF-α and chemokines such as monocyte 
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chemotactic protein (MCP)-1 and macrophage inflammatory protein (MIP)-1, and are 
thought to activate macrophages to destroy pathogens and enhance CD8+ CTL responses 
(Ley, 2014). Conversely, IL-4 induces naïve T cells to differentiate to CD4+ T Th2 cells 
which are characterised by production of IL-4, IL-5, IL-10 and IL-13 (Romagnani, 1991). 
Th2 cells are required to fight extracellular parasites, but are also involved in allergic 
inflammatory responses (Robinson et al., 1992). Their main effector cells are eosinophils, 
basophils, and mast cells as well as B cells, and IL-4/IL-5 CD4 T cells. The generation of 
Th1 and Th2 cells depends on transcription factors T-bet (Szabo et al., 2002) and GATA-3 
(Zheng and Flavell, 1997) respectively, which not only determine expression of cytokines 
including IFN-γ (Th1) and IL-4 (Th2 cells), but also help to maintain their phenotype.  
Both Th1 and Th2 cells have been reported to mediate anti-tumour immunity (Nishimura et 
al., 1999), although Th1 cells are thought to be more effective.  Th1 cells recruit NK cells and 
macrophages to the tumour site to eradicate it.  Production of IL-4 by Th2 cells may also 
exert anti-tumour effects via mobilisation of innate immune cells such as eosinophils (Tepper 
et al., 1989). Conversely, Th2 cells have been shown to induce proliferation and inhibit 
apoptosis of breast cancer cell lines in vitro, while secretion of Th1 (IFNγ) and Th2 (IL-4 and 
IL-13) cytokines has been reported to promote development of mammary carcinomas 
(Aspord et al., 2007; DeNardo et al., 2009). Consistent with these findings, Chin and co-
workers prepared tumour infiltrating lymphocytes (TIL) from 30 human breast cancers and 
demonstrated a correlation between a high levels of CD4+ cells and clinical tumour 
progression and metastasis (Chin et al., 1992; Sharma et al., 2009; Vukmanovic-Stejic et al., 
2006). Th2 cells have also been reported to promote neoplastic transformation and growth of 
pancreatic tumours (Ochi et al., 2012). 
Human IL17 producing CD4+ T cells (Th 17) were first described in 1990s in the context of 
chronic conditions such as airway inflammation and rheumatoid arthritis (Kotake et al., 1999; 
Teunissen et al., 1998) but were only recognized as a discrete T helper cell subset in 2005 
(Harrington et al., 2005; Park et al., 2005). Th17 cells develop in response to IL-6, IL-1 and 
TGFß, and express the defining transcription factor RORγt (Rorc) (Koenen et al., 2008; Voo 
et al., 2009). They are also induced through a STAT3-dependent mechanism by IL-9, IL-21 
and IL-10 (Zielinski et al., 2012). Th17 cells play an important role in protecting against 
extracellular pathogens by maintaining the integrity of mucosal surfaces but are also involved 
in the pathogenesis of many autoimmune diseases (Bettelli et al., 2008; Ouyang et al., 2008; 
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Zielinski et al., 2012). Th17 cells mediate their biological effects through production of 
signature cytokines IL-17A, IL-17F and IL-21 whose receptors are broadly expressed on 
epithelial tissues (Acosta-Rodriguez et al., 2007; Dong, 2008; Zielinski et al., 2012). IL-17A 
induces the expression of chemokines including CCL2, CCL7, CXCL1 and CCL20, as well 
as matrix metalloproteases (Park et al., 2005).  The functional contribution of Th17 to tumour 
immunity remains controversial, with evidence for both pro- and anti-tumour effects, 
depending on the tumour model and specific inflammatory conditions within the tumour 
microenvironment. Most data supporting an anti-tumour role is derived from murine models.  
For example, Martin-Orozco and colleagues demonstrated in a B16 melanoma model that IL-
17 depletion rendered mice more susceptible to lung metastasis while immunotherapy with 
Th17 cells induced a strong anti-tumour response mediated by tumour specific CD8+ T cells 
and DCs (Martin-Orozco et al., 2009b). In contrast, increased infiltration of Th17 cells in 
SCID mice bearing human non-small cell lung cancer (NSCLC) has been shown to promote 
angiogenesis and hence tumour growth (Numasaki et al., 2003; Numasaki et al., 2005). In 
humans also, a high percentage of CD4+ IL17-producing Th17 cells has been reported to 
correlate with poor prognosis in patients with prostate, colon, ovarian and hepatocellular 
tumours (Miyahara et al., 2008; Sfanos et al., 2008). . 
Follicular helper T (TFH) cells are able to migrate into follicles of secondary lymphoid 
organs where they promote B cell differentiation (Basso et al., 2010; Klein and Dalla-Favera, 
2008).  These cells are dependent on expression of the transcription factor Bcl-6 (Yu et al., 
2009), and identified by surface expression of CXCR5, inducible T cell co-stimulator (ICOS) 
and programmed cell death protein (PD)-1 (Breitfeld et al., 2000; Kim et al., 2001; Schaerli 
et al., 2000).  Analysis of tumour infiltrating immune cells in human colorectal and breast 
cancers has shown a correlation between the presence of TFH and B cells and patient survival 
(Coppola et al., 2011; Gu-Trantien et al., 2013)  
Induced regulatory T cells (iTregs) are immunosuppressive cells that maintain immunological 
tolerance to self-antigens (Oh and Li, 2013), and play an important role in protecting against 
autoimmune disease. iTregs develop in the thymus as a functionally mature T cell subset, but 
can also be induced in the periphery from naive T cells. The transcription factor Foxp3 is 
expressed by iTregs in response to IL-27 and IFNγ through a STAT1-dependent mechanism 
(Josefowicz et al., 2012; Sakaguchi et al., 2008).  
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Intra-tumour Tregs have been shown to inhibit effective immune responses against tumour 
cells, and high Treg:CD8 ratios in tumour tissue correlates with poor prognosis (Predina et 
al., 2013). There is also evidence that tumour-derived factors can promote the recruitment 
and proliferation of Tregs to the tumour site (Quezada et al., 2006), and elimination of Tregs 
has been shown to augment natural and pharmacological immunity (Betts et al., 2007; 
Tawara et al., 2002).   
1.5 CHRONIC INFLAMMATION AND TUMOUR DEVELOPMENT 
Rudolf Virchow first proposed in 1863 that chronic inflammation may lead to 
tumourigenesis, after he observed the presence of leukocytes in tumour tissues. This 
hypothesis is supported by numerous studies in a wide range of cancers (including melanoma, 
lung, breast, bladder, head and neck cancer) that demonstrate an association between chronic 
inflammation and increased risk of tumour development (Mastellos, 2009; Niculescu et al., 
1992). Preceding this, Leibovici and Hoenig (1985) found that increased macrophage density 
was associated with tumour growth and low macrophage numbers with tumour destruction. 
Further evidence that chronic inflammation promotes tumourigenesis comes from clinical and 
experimental studies demonstrating that prolonged administration of anti-inflammatory drugs 
such as COX2 inhibitors leads to a reduced risk of cancer development (Howe et al., 2001). 
Chronic inflammation is thought to promote tumour onset through mechanisms such as 
production of ROS (including peroxynitrites) and pro-angiogenic factors including VEGF 
and matrix metalloproteases which degrade the surrounding extracellular matrix (Balkwill et 
al., 2005; Coussens and Werb, 2002; Philip et al., 2004; Stutman, 1975).. The close 
association between inflammation and cancer suggests that pro-inflammatory components of 
the complement system may have a role in development and/or progression of malignant 
tumours. 
1.5.1 The complement system 
The complement system is an essential part of the innate immune system, regulating 
inflammation, facilitating immune defense mechanisms and maintaining tissue homeostasis 
(Ricklin et al., 2010). The complement system not only mediates innate immune responses to 
infectious organisms, damaged tissue and other foreign materials (Walport, 2001), but can 
also contribute to adaptive immunity (Dunkelberger and Song, 2010).  
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The complement system is an enzymatic cascade, comprising more than 30 highly regulated 
soluble proteins (C1 inhibitor, C4b binding protein, factor H and I, clusterin and vitronectin; 
synthesised primarily in the liver) and membrane bound receptors (CD35, CD46, CD55 and 
CD59) (Alper et al., 1969; Bonifati and Kishore, 2007; Morgan, 1999). The complement 
cascade can be triggered via four pathways (Figure 2), depending on the stimulus: the 
classical, alternative, lectin and extrinsic protease pathways (Ricklin and Lambris, 2007). The 
classical pathway is activated via interaction of antigen-antibody complexes with the 
multimeric collectin C1q (Loveland and Cebon, 2008). The alternative pathway is triggered 
by the presence of pathogen and interaction with foreign antigens on its surface, and accounts 
for up to 80% of complement activation (Ricklin and Lambris, 2007). Binding of mannan-
binding lectin (MBL) to carbohydrates on the pathogen surface activates the lectin pathway 
(Guo and Ward, 2005). Finally, the extrinsic pathway can be triggered directly by proteolytic 
enzymes such as thrombin and kallikrien, which results in cleavage of C3 and C5 
respectively (Ricklin and Lambris, 2007). The activation of classical and lectin pathways 
causes cleavage of C4 into C4a and C4b, of which C4b binds to C2, generating the 
classical/lectin C3 convertase (C4b2a complex) (Guo and Ward, 2005). The alternative 
pathway however, proceeds directly through C3 cleavage to generate an alternative pathway 
convertase (C3bBb). These convertases then lead to production of C3a and C3b which is a 
major opsonin that also forms a C5 convertase. 
Formation of membrane attack complexes (MAC) is a mechanism used by the complement 
system to eliminate foreign or infected cells directly via cell lysis. Initiation of membrane 
attack complex formation occurs upon cleavage of C5 by the C5 convertases to produce C5b 
which combines with C6, C7, C8, and multiple units of C9 (Jurianz et al., 1999). Cleavage of 
C3 and C5 also results in the production of the potent anaphylatoxins C3a and C5a (described 
in more detail below). 
Activation of the complement system is restricted by soluble and membrane bound regulatory 
proteins which protect both normal and neoplastic cells from damage. Membrane 
complement regulatory proteins (mCRPs) including CD35, CD46 and CD55 (complement 
receptor type-1; CR-1), membrane cofactor protein (MCP) and decay-accelerating factor 
(DAF) respectively regulate C3 activity. Membrane-bound protein, CD59, binds to C8 and 
C9 to prevent assembly of the MAC (Fishelson et al., 2003).   
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Overall, complement activation elicits a range of pro-inflammatory effects including 
increased vascular permeability, recruitment of leukocytes to damaged tissues, enhanced 
phagocytosis and damage to pathogen cell membranes (opsonisation), and cell lysis through 
the MAC (Ruddy et al., 1972). The ability of complement to participate in host defense is not 
limited to these innate immune activities however, with complement effector systems also 
contributing to efficient adaptive immune responses (Baruah et al., 2009; Baudino et al., 
2014; Cutler et al., 1998). Although the role of complement proteins in regulating T cell 
function is still not completely understood, the complement regulator DAF (CD55), which is 
expressed by most cells throughout the body, has been shown to have a role as a co-
stimulator of human T cell proliferation (Capasso et al., 2006; Davis et al., 1988). C1q is 
Figure 1.2. The Complement Cascade is activated via four pathways: the Classical, 
Alternative, Lectin and Extrinsic Pathways.  Initiation of all four pathways leads to 
formation of C3 convertase, a key component in the cascade, which cleaves C3 to its active 
fragments, C3a and C3b. C3b aids recognition and clearance of foreign material by 
macrophages (opsonisation) and formation of the membrane attack complex (C5b-9) 
which destroys invading pathogens. Additional bioactive products are anaphylatoxins C3a 
and C5a. Serine proteases of the coagulation cascade (Extrinsic Pathway) can also generate 
C5a. 
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known to prevent autoimmune T cell responses (Lalli et al., 2008; Strainic et al., 2008a) 
while anaphylatoxins C3a and C5a promote T cell activation and proliferation (see Section 
1.5.1.1), and thus promote allograft rejection, autoimmunity and responses to infection 
(Clarke and Tenner, 2014). However excessive complement activity, or deficiency of 
complement regulators, is known to contribute to a wide range of pathologic conditions 
including sepsis, asthma, rheumatoid arthritis, multiple sclerosis and acute respiratory distress 
syndrome (Guo and Ward, 2005).   
Historically, the complement system has been thought to contribute to anti-tumour defence 
mechanisms via complement dependent cytotoxicity (Ostrand-Rosenberg, 2008) and 
antibody-dependent cell mediated cytotoxicity (Gelderman et al., 2004). Indeed cancer cells 
are thought to evade complement-mediated destruction by up-regulating endogenous 
complement inhibitors (Hauschild et al., 2012; Macor and Tedesco, 2007). However recent 
studies have implicated the anaphylatoxin C5a for a role in regulating tumour growth 
(discussed in Section 1.5.4). 
1.5.2 Complement components C3a and C5a 
The complement components C3a and C5a are anaphylatoxins through which the 
complement system exerts many of its effects. Both C3a and C5a molecules are highly 
cationic with a core structure of 4 helix bundles stabilised by three disulphide bonds (Klos et 
al., 2009). C5a is a small peptide comprising 74 amino acids (el-Lati et al., 1994). It is one of 
the most potent inflammatory proteins known, exerting its activity at low nanomolar 
concentrations upon binding to specific receptors C5aR1 (CD88) and C5aR2 (C5L2) (Guo 
and Ward, 2005). C3a consists of 77 amino acids, and has 36% overall homology to the C5a 
sequence, with higher homology in the C-terminal “active” region of the molecule 
(Takabayashi et al., 1996). It exerts its main biological effects by binding to a single receptor, 
C3aR, although other receptors and functions for C3a have been identified (Coulthard and 
Woodruff, 2015). 
All three receptors (C5aR1 and C5aR2 and C3aR) belong to the superfamily of G-protein-
coupled receptors and are expressed by myeloid cells including monocytes, eosinophils, 
basophils and neutrophils (Gerard et al., 1989), as well as lymphocytes (Eden et al., 1973; 
Okada and Nishioka, 1973; Ross et al., 1973). They can also be expressed by non-myeloid 
cells, especially in lung and liver (Haviland et al., 1995; Klos et al., 2009; Schieferdecker et 
al., 2001).  
   25 
 
C5a binds both of its receptors with high affinity although it exerts most of its described 
biological activity via binding to C5aR1 (Guo and Ward, 2005). C5aR2 lacks G-protein 
coupling, and thus was originally thought to be a “decoy” or scavenger receptors binding 
excess C5a without exerting direct physiological effects (Gao et al., 2005). However there is 
emerging evidence to suggest that C5aR2 can independently induce and moderate biological 
functions of C5a through β-arrestin signalling (Bamberg et al., 2010; Croker et al., 2014; Li 
et al., 2013).   
C5a binding to C5aR1 activates signalling pathways such as calcium mobilisation via 
phospholipase Cβ, adenyl cyclase/cAMP production, PI3K/AKT and MAPK (Klos et al., 
2013) to stimulate a range of pro-inflammatory responses. These include chemoattraction of 
macrophages, neutrophils, activated B and T cells, basophils and mast cells (Guo and Ward, 
2005; Woodruff et al., 2011), enhanced phagocytosis (el-Lati et al., 1994) and stimulation of 
cytokine release.  It triggers histamine release from basophils and mast cells (Kretzschmar et 
al., 1993) which in turn stimulates vasodilation and increased vascular permeability (Ember 
et al., 1998), as well as production of the angiogenic growth factor, VEGF-A.  It can also 
stimulate angiogenesis directly by promoting the migration of microvascular endothelial 
cells.  C5a stimulation of neutrophil degranulation causes the release of toxic mediators and 
matrix metalloproteinases (Lacy, 2006; Martinelli et al., 2004). In addition, C5a links to the 
adaptive immune system, influencing the trafficking and migration of B-cell populations 
(Kupp et al., 1991; Ottonello et al., 1999) and modulating T-cell responses by providing 
survival signals for naïve CD4+ cells (Strainic et al., 2008b), inhibiting induction and function 
of Tregs (Strainic et al., 2013) and promoting T cell activation during interaction with APCs 
in vitro and in vivo (Cravedi et al., 2013). C5aR1 synergises with Toll-like receptor (TLR)-4 
to elicit a stronger inflammatory response (Zhang et al., 2007) whereas C5aR1 antagonism 
has been shown to reduce the CD8 T cell response to influenza A in mice (Kim et al., 2004).  
Binding of C3a to C3aR induces intracellular signal transduction pathways, including 
calcium mobilisation, ERK and AKT (Venkatesha et al., 2005). Compared to C5a, C3a is a 
much weaker chemoattractant (Fernandez et al., 1978) but has a range of immunomodulatory 
functions including degranulation of eosinophils, basophils and mast cells (el-Lati et al., 
1994; Takafuji et al., 1994) and stimulation of cytokine expression by 
monocytes/macrophages (Norgauer et al., 1993; Zhang et al., 2007). C3aR is also a key 
mediator of insulin resistance and functions by modulating macrophage infiltration and 
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activation in adipose tissue (Mamane et al., 2009). It has also been reported to negatively 
regulate the mobilisation of haematopoietic stem and progenitor cells from the bone marrow 
(Ratajczak et al., 2004; Reca et al., 2003) while Wu et al (2013) showed that C3aR prevents 
neutrophil egress into the circulation, thus reducing acute tissue injury after ischemia (Wu et 
al., 2013).  Like C5a, C3a signalling also contributes to the regulation of adaptive immunity.  
B cells have been reported to express C3aR, and C3a has been shown to negatively regulate 
antibody responses (Fischer and Hugli, 1997; Morgan et al., 1982). Moreover C3a has been 
reported to promote T cell activation, with C3aR required for CD4+ and CD8+ T cell 
responses to Chlamydia psittaci infections (Dutow et al., 2014).  C3a may also affect T cell 
responses indirectly via antigen-presenting cells, with C3a signalling in bone marrow derived 
dendritic cells shown to enhance IL-23 and IL-6 production and promote Th17 differentiation 
in a mouse model of allergic asthma (Lajoie et al., 2010). An absence of C3aR and C5aR1 
signalling in CD4+ T cells has been shown to lead to enhanced IL10 and TGFβ expression 
and Foxp3 iTreg-mediated immunosuppression (Strainic et al., 2013) whereas C3aR/C5aR1 
signalling abrogates nTreg function (Kwan et al., 2013). Although Strainic et al (2013) 
showed that a combination of C3aR/C5aR1 inhibition and TGFβ induced the development of 
functional Tregs(et al., 2013), the effect of C5aR1 signa1ling on the malaria-specific CD4+ T 
cell response was shown to be indirect via inhibition of DCs (Liu et al., 2013). 
Despite their critical role in the development of effective immune responses, excess 
production of C5a and C3a can lead to up-regulated pro-inflammatory responses, resulting in 
tissue damage and eventually multi-organ failure (Gao et al., 2005). Indeed the 
anaphylatoxins have been implicated in a range of inflammatory diseases including 
rheumatoid arthritis, ischemia-reperfusion injury, sepsis, neurodegenerative diseases and 
macular degeneration (Bonifati and Kishore, 2007; Guo and Ward, 2005; Manderson et al., 
2004; Zipfel et al., 2006). Thus, the regulation of anaphylatoxin receptor activation may have 
therapeutic benefits in a wide range of diseases. To this end, a number of agonists and 
antagonists have been developed which may lead to effective therapies for these diseases. 
1.5.3 Peptide agonists and antagonists of anaphylatoxins C3a and C5a 
The development of agonists and antagonists for complement components has provided 
researchers with important tools to dissect the roles of the complement anaphylatoxins. A 
number of peptide agonists have been developed based on the native C-terminal sequences of 
C3a and C5a (Taylor et al., 2001). One of these peptides, termed EP141 (amino acid 
   27 
 
sequence WWGKKYRASKLGLAR) was developed by Ember and co-workers (1991) and is 
a highly potent and selective agonist of C3aR. This peptide contains a region with the 
essential functional site of the molecule, which interacts with the binding site on the C3a 
receptor(Ember et al., 1991). Another complement anaphylatoxin analogue, EP54 (amino 
acid sequence YSFKPMPLaR) is selective for C5aR1 and C3aR (Tempero et al., 1997), and 
demonstrated to act as molecular adjuvant, targeting C5aR1 on dendritic cells (Hegde et al., 
2008).  
A series of cyclic peptide C5aR1 antagonists have also been developed at The University of 
Queensland that are selective inhibitors of C5aR1 (Strachan et al., 2000). Two key 
compounds, termed PMX53 (AcF-[OPdChaWR]) and PMX205 (HC-[OPdChaWR]), are 
orally active, specific C5aR1 antagonists (March et al., 2004)  These compounds prevent 
C5a-mediated release of pro-inflammatory mediators TNF-α and IL-6 both in vivo and in 
vitro (Proctor et al., 2004) and have been shown to effectively reduce C5a-mediated 
inflammatory responses in numerous animal models of disease, including arthritis (Woodruff 
et al., 2011) ischaemia-reperfusion injury and stroke (Arumugam et al., 2004; Woodruff et 
al., 2004), inflammatory bowel disease and atherosclerosis (Manthey et al., 2011; Proctor et 
al., 2004; Woodruff et al., 2003). Although several other C5aR1 antagonists have been 
reported in the literature (Woodruff et al., 2011), to date the PMX-series of molecules are the 
only compounds with robust activity in multiple chronic disease models, making them ideal 
therapeutic tools to study C5aR1 pathobiology in vivo. 
SB290157 is a non-peptide arginine analogue that acts as a competitive antagonist with high 
affinity and specificity for the C3a receptor (Ames et al., 2001). It exhibits anti-inflammatory 
properties, and has been shown to block C3a-induced internalization of C3aR in human 
neutrophils and C3a-induced Ca2+ mobilization in basophilic leukaemia RBL-2H3 cells 
expressing murine, guinea pig, or human C3aR.  Anti-inflammatory activity has also been 
demonstrated, due to effects on neutrophil populations (Proctor et al., 2004). However 
SB290157 has a short half-life (Denonne et al., 2007), and has been reported to have agonist 
properties in a number of cellular systems (Mathieu et al., 2005), possibly depending on the 
level of receptor expression. These data caution against the sole reliance on this compound to 
assign roles for C3aR; rather additional studies using other supporting methods, such as 
C3aR-/- animals, are required to definitively ascribe functions to C3aR (Woodruff and 
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Tenner, 2015). Clearly, there is a continuing need for the development of potent and selective 
C3aR antagonists for interrogating and potentially treating C3a-mediated conditions. 
1.5.4 The complement anaphylatoxins and tumour growth 
The detection of complement activation products, including C4d (Ajona et al., 2013) and C5a 
(Gorter and Meri, 1999; Niculescu et al., 1992) in tumour tissue, as well as elevated C5a 
(Corrales et al., 2012) and C3a (Habermann et al., 2006; Jinong Li, 2002; Kanmura et al., 
2010; Maher et al., 2011; Solassol et al., 2010) levels in serum from cancer patients, suggests 
that the complement system is activated in response to tumours. Indeed tumour cells are 
thought to escape immune attack by up-regulating complement regulatory proteins (Fishelson 
et al., 2003; Varela et al., 2008; Watson et al., 2006; Zell et al., 2007).  Enhanced expression 
of complement regulatory proteins has been shown to protect against complement mediated 
lysis of tumour cells (Gorter and Meri, 1999; Jurianz et al., 1999; Varsano et al., 1998) 
whereas treatment with antibodies against tumour antigen and the complement lysis inhibitor 
protectin (CD59) lead to eradication of micro-metastases and small solid tumours from breast 
carcinoma and ovarian teratocarcinoma cell lines by complement-mediated mechanisms 
(Hakulinen and Meri, 1998).  
To date, the majority of studies investigating the role of complement anaphylatoxins in 
tumour growth have been directed towards C5a, and these have yielded conflicting results.  
C5a has been utilised as a molecular adjuvant to enhance the efficacy of antibodies to tumour 
antigens. For example Fuenmayor et al. (2010)  demonstrated that the tumouricidal effect of a 
monoclonal antibody against human epidermal growth factor receptor 2 (HER2/neu) was 
enhanced by fusion with C5a. These fusion proteins facilitated chemotaxis of human 
granulocytes, which are the primary immune effector cell responsible for facilitating antibody 
dependent cell mediated cytotoxicity (ADCC).  
Kim et al (2005) showed that over-expression of C5a by mouse mammary tumour cells 
protected against tumour growth .  They suggested that C5a can either act directly on tumour 
cells by inhibiting their growth through apoptosis and cell cycle arrest, or indirectly by 
activating tumour infiltrating inflammatory cells (macrophages and/or granulocytes) to 
eliminate the tumour by phagocytosis or via cytokine secretion and production of ROS.  The 
demonstration that mice were immune to subsequent challenge with normal tumour cells (ie 
not transduced with the C5a construct) suggested the involvement dendritic cells and the 
adaptive immune response.  Further evidence for a protective role for C5a against mouse 
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mammary tumours has been provided by Hezmee (2010) and Akhir (2014) who showed that 
the growth of mouse mammary tumours could be inhibited by daily treatment with the dual 
C3a/C5a agonist, EP54.  
Studies on other tumour types have implicated C5a for a tumour promoting role. Markiewski 
et al (2008) convincingly demonstrated that deficiencies in complement components C3 or 
C5a were associated with retarded tumour growth in a mouse cervical cancer model, while 
pharmacological blockade of C5aR1 using PMX53 contributed to tumour regression. Their 
results suggested that this effect was due to the ability of C5a to recruit myeloid derived 
suppressor cells which in turn suppress the tumour-specific immune response. C5a was also 
shown to increase the production of reactive oxygen (ROS) and nitrogen (RNS) species by 
these cells . Similarly Corrales et al. (2012)demonstrated in a murine model of lung cancer 
that C5aR1 antagonism retarded tumour growth.  C5a appeared to promote an 
immunosuppressive microenvironment, with C5aR1 antagonism attenuating MDSCs, 
including the granulocytic subpopulation; immunosuppressive molecules, including ARG1, 
CTLA4, IL-6, IL-10, LAG3 and PDL1, were also down-regulated.  C3 and C5aR1 
deficiencies have also been reported to profoundly impair growth of a transgenic murine 
model of epithelial ovarian cancer (Nunez-Cruz et al., 2012).  However, in this case, 
complement inactivation did not alter the inflammatory infiltrate within tumours, but reduced 
tumour vascularisation via inhibition of specific VEGF isoforms.   
Although C5a may have different effects in different tumour types, Gunn and co-workers 
(2012) have suggested that the concentration of C5a within the tumour microenvironment is 
critical in determining its effects. They found that mice bearing high C5a-producing 
syngeneic lymphomas had significantly accelerated tumour progression with more Gr-
1+CD11b+ myeloid cells in spleen and overall decreased CD4+ and CD8+ T cells in tumour, 
tumour-draining lymph nodes (TDLN), and spleen. Conversely, mice with low C5a-
producing lymphomas had significantly reduced tumour burden with increased IFN-γ-
producing CD4+ and CD8+ T cells in spleen and TDLN.  
Recent studies have provided evidence that C5a may also contribute to development of 
tumour metastasis.  The first direct evidence that C5a promotes tumour metastasis was 
provided by Vadrevu et al. (2014) who showed in a murine breast cancer model that lung 
metastasis are reduced in the absence of C5aR1 signalling.  They showed that inhibition of 
C5aR1 signalling results in the down regulation of MDSCs, Treg cells and 
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immunosuppressive cytokines such as TGF-ß and IL-10, but increased levels of CD4+ and 
anti-tumour CD8+ T-cells in the pre-metastastic niche. Conversely, C5aR1 blockade did not 
affect primary tumour growth.  More recently, Piao and co-workers (2015)have shown that 
C5a contributes to hepatic metastasis of colon cancer. The absence of C5aR1 reduced the 
infiltration of macrophages, neutrophils and dendritic cells whereas C5a signalling increased 
the expression of the chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) and 
anti-inflammatory cytokines IL-10 and TGFβ. 
Despite the growing data regarding the effects of C5aR signalling on tumour immunity, the 
role of C3aR remains elusive. Up-regulated levels of serum C3a have been reported in many 
cancers including breast, colorectal and oesophageal cancer (Maher et al., 2011; Medina-
Echeverz et al., 2014), and gene expression analysis has identified the up-regulation of C3a 
receptor (C3aR) by some tumours, including melanoma (Xu et al., 2008).  A recent report by 
Cho and co-workers (2014)  demonstrated the expression of both C3aR and C5aR by ovarian 
cancer cells.  They further showed that these receptors are capable of signal activation via the 
P13K/AKT pathway to induce cell proliferation, migration and invasion.  Conversely 
receptor inhibition reduced cell proliferation, leading these researchers to conclude that 
tumour-derived complement proteins are capable of promoting tumour growth via autocrine 
mechanisms. They also applied data mining techniques using Cancer Cell Line 
Encyclopaedia (CCLE) database to identify high level of C3 expression in liver, kidney, lung, 
endometrial and ovarian cancer cell lines (Cho et al., 2014). In another recent study, Surace et 
al (2015) have reported that the local production of C3a and C5a are critical to the anti-
tumour response induced by radiotherapy.  Additional indirect evidence that C3a, as well as 
C5a, may play a role in tumour growth was provided by an earlier study showing that both 
C3aR- and C5aR1-deficient mice had reduced levels of neovascularisation, VEGF and blood 
vessel formation, all critical factors for tumour perfusion and invasion (Nozaki et al., 2006).  
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1.6 CONCLUSIONS AND PROJECT RATIONALE 
Although the relationships between inflammation and cancer are well recognized, the roles of 
key inflammatory mediators (complement components C3a and C5a) are yet to be completely 
elucidated. The presence of complement activation products and expression of complement 
receptors by cancerous cells are well established, and in the last few years the contribution of 
C5a in tumour growth has been demonstrated, albeit with different mechanisms in different 
tumour types.  However, despite evidence that serum C3a levels are up-regulated in many 
cancer patients, and that C3aR is expressed by some tumour cells, there is little information 
concerning the role of C3a in tumour growth. Therefore, this thesis investigated the effects of 
both C3a and C5a in mouse tumour models.  
We hypothesised that complement anaphylatoxin receptors C3aR, C5aR1 and C5aR2 are 
therapeutic targets for melanoma. The specific aims of this study were: 
1) To investigate the expression of complement anaphylatoxin receptors in murine and 
human melanoma cell lines; 
2) To identify the roles of C3aR, C5aR1 and C5aR2 in tumour growth in a mouse model of 
melanoma, and to identify the therapeutic potential of C3aR or C5aR pharmacological 
antagonism;  
3) To investigate the mechanisms underpinning the observed responses, by studying tumour 
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MATERIALS & METHODS 
2.1 Cell Lines 
The murine melanoma B16-F0 (ATCC® CRL6322™; (Fidler and Nicolson, 1976), B16-F10 
(ATCC ® CRL-6475™) and murine J774A.1 macrophage (ATCC® TIB-67™) cell lines (all 
syngeneic in C57BL/6J mice) were obtained from the American Type Culture Collection 
(Manassas, VA).  Murine SM1WT1 melanoma cells (Knight et al., 2013) and MC38 colon 
cancer (Rosenberg et al., 1986) cell lines were provided by Prof Mark Smyth (QIMR 
Berghofer Medical Research Institute), and human metastatic melanoma (MM603, MM608, 
HT144, MM370 and MM649), BRAFV600E mutant (Mel-RMu) and primary melanoma 
(MM96L) cell lines by Dr. Glen Boyle (QIMR Berghofer Medical Research Institute). B16, 
SM1WT1 and MC38 cells were cultivated in high glucose Dulbecco's modified Eagle 
medium (DMEM; Invitrogen, Auckland, NZ), and human melanoma and J774 cells in RPMI 
supplemented with 10% heat-inactivated foetal calf serum (FCS; Moregate, Brisbane, Aust) 
and penicillin/streptomycin at 37 °C in a humidified atmosphere of 5% CO2 in air.   
2.2 Drugs 
The selective C5aR1antagonist, AcF-[OPdChaWR] (PMX53) was provided by Assoc. Prof. 
Trent Woodruff from School of Biomedical Science, The University of Queensland, 
Australia, and prepared in an isotonic 5% glucose/water solution. The C3aR antagonist 
SB290157, N2-[(2,2-Diphenylethoxy)acetyl]-L-arginine trifluoroacetate (VDM Biochemicals 
Inc, Bedford Heights, OH) was prepared in 10% ethanol, and diluted in sterile saline.  
2.3 Animals 
Homozygous C57BL/6J congenic C3aR, C5aR1 and C5aR2 receptor knockout (C3aR -/-, 
C5aR-/- and C5aR2-/-) or wild-type (WT; C57BL/6J) mice (6-8 weeks old, and sex-matched) 
were obtained from University of Queensland Biological Resources and fed a normal chow 
diet ad libitum.  All procedures were approved by the University of Queensland Animal 
Ethics Committee Guidelines (AEC 493/09 and 564/12) and conformed to the Animal Care 
and Protection Act Qld (2002) and the Australian Code of Practice for the Care and Use of 




2.4 Tumour Induction and Drug Treatments 
For induction of primary melanomas, WT, C3aR -/-, C5aR1-/- or C5aR2-/- mice (n=6-8 
animals/group) were clipped over the right flank before subcutaneous (s.c.) injection of B16-
F0 cells (2.5x105 cells/mouse) or SM1WT1 (1x106 cells/mouse) in 0.05 ml serum-free 
medium.  Colon carcinoma cells (1x106 cells/mouse) were injected s.c. into the left flanks of 
mice.  Tumour growth was monitored daily and measured by Vernier callipers from day 5 
after tumour cell injection.  For some experiments, C57BL/6J mice received daily i.p. 
injections (0.05 ml) of either C3aR antagonist (SB290157; 1 mg/kg/day) or vehicle only 
(10% ethanol in normal saline) control; other mice received s.c. injections of PMX53 (1 
mg/kg/day) or vehicle only (5% glucose) control (n=6-8 animals/group), commencing once 
tumours became palpable (approx. day 7 after tumour cell injection).  For most experiments, 
mice were euthanized at day 14 (or once the largest tumour reached an area of approx 200 
mm2), tissue removed for either flow cytometry or histological analysis (n=6-8/group), and 
tumours weighed.  For ‘survival’ studies, the time taken for each tumour to reach maximal 
size (200 mm2) was recorded, then mice euthanized.  
For neutrophil depletion experiments, WT and C3aR-/- mice (n=8/group) were injected i.p. 
with anti-Ly6G antibody (1A8, selective for neutrophils, 0.1 mg/mouse; Bio X Cell (Daley et 
al., 2008) or isotype control (rat IgG2a, 2A3) 24 hours prior to s.c.. injection of B16 cells, and 
then every 3 days until the largest tumour reached 200 mm2.  Mice were then euthanized, and 
blood and tumour tissue removed and weighed.  
2.5 Tissue Processing and Histology 
Harvested tumour tissue was fixed overnight at 4 °C in 4% paraformaldehyde (PFA; Electron 
Microscopy Sciences, Hatfield, PA), then washed with phosphate buffered saline (PBS) 
before infusing with 18% sucrose at 4 °C overnight.  The sucrose solution was then replaced 
with a solution containing (O.C.T Compound Sakura Fine technical, Tokyo, Japan) and 
frozen on liquid nitrogen. Tissue blocks were stored at -20 °C prior to cryosectioning (Hyrax 
C60, American Optical Corporation, USA), and 5 µm sections dry mounted onto glass slides. 
Sections were air dried at room temperature for several hours and stored at -20 °C under 





2.6 Immunofluorescence Staining  
B16, MM96L and J774 cells were seeded (at approx 2.5x104cells/cm2) onto glass cover slips 
and attached overnight before fixing with 4% PFA for 10 mins.  Cells were either non-
permeabilised (for membrane staining) or detergent-permeabilised (for intracellular staining) 
by incubation in 0.1% triton X-100 (Sigma-Aldrich) in PBS for 30 seconds. Cells on 
coverslips or frozen sections were then incubated with blocking buffer (1% bovine serum 
albumin (Sigma-Aldrich), 5% sheep serum in PBS) for 30 mins, followed by primary 
antibodies (Table 2.1) overnight at 4°C. After washing with PBS, cells or tissue sections were 
incubated with their respective secondary antibodies (Table 2.2) for 1 hour at room 
temperature in the dark. Alternatively cells or tissues were incubated with directly conjugated 
primary antibodies for 2 hrs at room temperature. After further washing, nuclei were stained 
with Hoechst 33342 (1:2000; Life Technologies) for 10 minutes. Cells or tissue sections were 
washed again, then mounted in ProLong Gold anti-fade reagent (Life Technologies), 
examined under an Olympus BX-61 microscope (Tokyo, Japan) and photographed with a 
Retiga EXi cooled CCD camera (Olympus). 
2.7 Immunohistochemistry  
Formalin-fixed paraffin embedded human melanoma cell pellets or paraffin embedded human 
melanoma tissue arrays (AccuMax Array, Biomax, Rockville, MD) were de-paraffinised 
prior to incubation in 0.25% potassium permanganate and 1% oxalic acid for 10 minutes and 
1 minute, respectively to bleach the melanin. Sections were then incubated for 10 minutes in 
1% glycine solution in PBS to balance any change in charge followed by antigen retrieval by 
microwaving in 10-2 mol/L citrate buffer, pH6 (Antigen Unmasking Solution, Vector 
Laboratories; Burlingame, CA) for 20 minutes. This was followed by overnight incubation 
with primary antibodies (Table 2.1) diluted in blocking buffer (3% goat serum in PBS) at 4 
°C. Sections were washed in PBS then incubated for 30 minutes with the appropriate 
biotinylated secondary antibody, followed by Streptavidin-peroxidase ABC (Vector), and 
AEC (Vector) as substrate, then once the desired colour developed, sections were lightly 
counterstained with haematoxylin and mounted with Vectamount (Vector).  
Human neutrophils in paraffin embedded tissue were detected using a Naphthol AS-D 




Images of stained tissue sections were collected on an Aperio Scanscope digital slide scanner 
(Leica Biosystems, Nussloch, Germany) 
Table 2.1 Primary antibodies used for immunostaining  
Antibody Host Manufacturer Dilution 
Anti-mouse C3aR Chicken Bachem 1/100 
Anti-mouse C5aR  Rat AbD Serotec  1/100 
Anti-mouse C5L2 Rabbit Hycult Biotech 1/200 
FITC Anti-mouse CD45 Rat eBioscience 1/100 
Anti-human C3aR Mouse BioLegend 1/50 
Anti-human C4d Rabbit Biomedica 1/50 
 
Table 2.2 Secondary antibodies used for immunostaining 
Antibody Host Manufacturer Dilution 
FITC anti-Rat IgG Chicken Millipore 1/200 
Alexa Fluor 488 anti-rat IgG Goat Life Technologies 1/100 
Alexa Fluor 555 anti-chicken IgG Goat Life Technologies 1/500 
Alexa Fluor 488 anti-chicken IgG Goat Sigma-Aldrich  1/600 
Biotinylated anti-mouse IgG Goat Life Technologies 1/200 
Biotinylated anti- rabbit  Goat Life Technologies 1/200 
 
2.8 Western analysis 
B16 cells were grown to approx 70% confluence in T-25 culture flasks, followed by serum 
starvation (in DMEM without FCS) for 24 hours. Cells were then treated with either dual 
C3a/C5a agonist (EP54), C3a agonist (EP141 at 10 µmol/L) or DMEM alone for the times 
indicated in the experiment.  After treatment, crude protein extracts were obtained by 
disrupting the cells in RIPA lysis buffer [50 mmol/L Tris HCl pH 7.4, 150 mmol/L NaCl, 1% 
NP-40, 0.25% sodium deoxycholate, 1 mmol/L EDTA, 1 mmol/L Na3VO4, 1 mmol/L PMSF, 
5 mmol/L NaF, 1 mmol/L DTT, 1X protease inhibitor cocktail (Sigma)].  For each sample, 




SDS-PAGE on 8% polyacrylamide gels (Laemmli, 1970), then separated proteins 
electrotransferred (Towbin et al., 1979) to a PVDF membrane (Immobilon P; Millipore, 
Billerica, MA).  Membranes were blocked (Blocking Buffer; Li-Cor Biosciences, Lincoln, 
NE), before incubation with primary antibodies (anti-phospho-AKT and anti-total AKT (Cell 
Signalling, Danvers, MA) or mouse anti-diphosphorylated ERK1/2 and rabbit anti-total 
ERK1/2 (Sigma-Aldrich) followed by fluorescently-labelled secondary antibodies (IR Dye 
800CW-goat anti-mouse Ig and IR Dye 680LT anti-rabbit Ig; Li-Cor Biosciences; Lincoln, 
NE). Immunoreactive bands were visualised by scanning on an Odyssey Imaging System (Li-
Cor Biosciences) and the percentage phosphorylated protein relative to total protein 
determined using Odyssey V3.0 image analysis software. 
2.9 Cell proliferation (MTT assay) 
Cell proliferation was measured using a CyQUANT® NF cell proliferation assay kit (Life 
Technologies), according to the manufacturer's instructions. Briefly, cells were seeded at 
5x103 cells/well into a 48-well plate, and allowed to attach overnight. After serum-starving 
(in DMEM + 2% FCS) for 24 hours, cells were treated with PMX53 (1μmol/L in the same 
medium) or mouse C5a (10-9 mol/L), mouse C3a (10-8 mol/L) for a further 48 hours. Medium 
was then removed, cells washed with HBSS. Cell proliferation rates were determined by 
incubation with 10 μL, 12 mmol/L MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide reagent until purple precipitate is visible (approx 2-4 hours), 
then 100 μL of detergent reagent added and the plates kept in the dark for 2 hours. After 
mixing each sample, absorbance was read at 570nm.   
2.10 Cell migration assay  
To investigate the effect of C3aR agonist on B16 migration, cells were seeded at confluence 
(2x105 cells/cm2) into a 24 well plate, adhered overnight and then confluent monolayers 
scratched with a pipette tip before being treated for 24 hours with C3aR agonist (10-6 mol/L); 
control wells were incubated with medium alone or containing 5% FCS.  Migration was 




2.11 Flow cytometric analysis 
Blood was collected by cardiac puncture, tumours, spleen, draining lymph nodes (inguinal, 
axillary and brachial) and femurs excised; tumours were weighed, and femurs flushed with 
PBA (PBS containing 0.2% BSA, 0.1% sodium azide, 5% rat serum) using a syringe with a 
25-gauge needle to obtain bone marrow cells.  Single cell suspensions of tumour, spleen and 
draining lymph nodes were prepared by passing tissues through a 70 μm nylon cell strainer 
(Becton Dickinson) into PBS containing 0.1% BSA (Sigma-Aldrich, St.Louis, MO) and 0.1% 
sodium azide (NaN3; Sigma-Aldrich) (PBA).  Blood and spleen cell suspensions were 
incubated in lysis buffer (155 mmol/L NH4CL, 10 mmol/L KHCO3, 0.1 mmol/L EDTA; all 
from Sigma-Aldrich) for 10 minutes at 4 °C to lyse red blood cells. Cells were washed in 
PBA and distributed into clear, U-bottom 96 well plates (0.5-2.0x105 cells/well) before 
centrifugation at 400 g for 5 min at 4 °C.  Supernatants were removed and cells pre-incubated 
with blocking buffer (5% normal rat serum and anti-CD16/32 (TruStainFcX, 1/50; 
BioLegend, San Diego, CA) in PBA) for 15 minutes to block Fcγ receptor binding prior to 
surface staining with fluorophore-conjugated monoclonal antibodies (MAb) (Table 2.3) or 
the appropriate isotype controls at 4 °C for 30 minutes.  For staining of Treg cells, cells were 
stained with antibodies to surface antigens, then fixed and permeabilised with FoxP3 
Fix/Perm kit (BioLegend), and incubated for 40 mins with anti-FoxP3.  For Th1, Th2, Th17 
staining, cells were first stimulated for 4 hours (37 °C) with phorbol myristate acetate (PMA, 
50ng/ml; Sigma) and ionomycin (1 µmol/L; Sigma) in the presence of Brefeldin A (5µg/ml; 
BioLegend).  After surface staining (as above), cells were fixed with Fixation Buffer and 
permeabilised with Permeabilisation/Wash Buffer (BioLegend) before incubation for 40 mins 
at room temperature with fluorophore-conjugated antibodies to IL-4, IL-17A or IFN-γ (all 
from BioLegend).  After antibody staining, cells were washed twice in PBA, then 
resuspended in 100 μl PBA.  For detection of C3a receptor, cells were incubated with 
primary anti-human C3aR antibody for 30 minutes followed by 40 minutes incubation with 
biotinylated anti-mouse IgG, then washed twice in PBS and resuspended in 100 μl PBS for 
flow cytometry.  Compensation was performed using compensation beads (BD Biosciences).  
All cells were analysed using an Accuri C6 flow cytometer (BD Biosciences) and data 
analysed using FlowJo software package (Tree Star Inc., Ashland, OR).  Gating strategies for 





Figure 2.1. Flow cytometry and gating strategies for the tumour inflammatory infiltrate. 
Representative contour plots show different infiltrating leukocyte subpopulations in 
tumour tissue. Debris (SSC-A vs. FSC-A) were excluded, then leukocytes (CD45+ cells; 
A) were sub-gated for monocytes (CD11b+Ly6C+; B), neutrophils (CD11b+Ly6G+; C), 
MDSC (CD11b+GR1+; D), macrophages (F480+; E) and total T lymphocytes (CD3+; F). 
Total T lymphocytes were sub-divided into CD4+ (G; red) and CD8+ (G; orange) 
populations. CD4+ cells were further sub-gated into Tregs (CD4+CD25+FOXP3+; H) , Th1 
(CD4+IFNγ+; I), Th2 (CD4+IL4+; J) and Th17 (CD4+IL17+; K). For each sub-gate, the 





Table 2.3 Antibodies used for FACS analysis 
2.12 Cytokine Assay 
Blood was taken by cardiac puncture into EDTA tubes, centrifuged at 1800 g for 5 minutes at 
4 °C, and plasma collected and stored at -80 °C until assay.  Snap frozen tumour tissue was 
pulverised with a mortar and pestle, then cytoplasmic extracts prepared according to 
manufacturers’ instructions (Milliplex Cell Lysis Kit; Millipore).  Protein concentration was 
determined by BCA assay, and equal amounts of total protein (0.25 mg/assay) analysed by 
Antibody Manufacturer Dilution 
APC/647 rat anti-mouse 
 
AbD Serotec 1/100 
FITC rat anti-mouse CD45 BioLegend 1/400 
 PE/Cy7 rat anti-mouse CD45 BioLegend 1/400 
PE/Cy7 rat anti-mouse F4/80 BioLegend 1/400 
Alexa Fluor 488 rat anti-
  
BioLegend 1/400 
PE  rat anti-mouse CD11b BioLegend 1/300 
FITC rat anti-mouse Gr-1 BioLegend 1/200 
FITC rat anti-mouse Ly6G 
 
BioLegend 1/300 
APC/647  rat anti-mouse 
  
BioLegend 1/300 
PE/Cy7 rat anti-mouse Ly6C BioLegend 1/300 
APC/647 rat anti-mouse 
 
BioLegend 1/200 

















FITC rat anti-mouse CD3 BD Biosciences 1/300 
FITC rat anti-mouse CD4 BD Biosciences 1/300 
FITC rat anti-mouse CD8a BD Biosciences 1/300 
PE rat anti-mouse FoxP3 BioLegend 1/200 
PE/Cy7 rat anti-mouse CD25 BioLegend 1/300 
PE rat anti-mouse IL4 BioLegend 1/200 
PE rat anti-mouse IL17 BioLegend 1/300 
APC/647  rat anti-mouse 
 
BioLegend 1/300 








multiplex ELISA (Mouse Cytokine/Chemokine Panel; Millipore) according to the 
manufacturer’s instructions.    
2.13 Statistical Analysis 
Each experiment was performed a minimum of 3 times and statistical analyses were 
performed using the statistical software package Graph Prism v5.04.  Results are expressed as 
mean ±  SD.  Tumour growth curves were analysed by Permutation test and survival studies 
by log-rank Mantel-Cox test.  All other data were analysed by Mann-Whitney test or Kruskal 
Wallis test followed by Dunn’s multiple comparisons test.  For all tests, a P value of <0.05 










THE OPPOSING EFFECTS OF COMPLEMENT 
C5A RECEPTORS, C5AR1 AND C5AR2, IN A 
MOUSE MODEL OF MELANOMA 
 
 









Melanoma is the most aggressive form of skin cancer, with 232,000 new cases and 55,000 
deaths reported globally in 2012 (World Health Organisation Report, 2014).  Despite recent 
advances in treatment, sustained responses remain elusive and the 3-year survival rate for 
metastatic melanoma remains around 15% (Eggermont et al., 2014).  There is therefore an 
urgent need for new therapeutic strategies for advanced melanoma.  Given the evidence that 
the complement system is activated in response to tumour cells (Ajona et al., 2013; Niculescu 
et al., 1992), along with recent studies demonstrating a role for complement activation 
product C5a in regulating the growth of some tumour types, this chapter investigated the role 
of C5a in melanoma.    
The complement system is activated via several routes, all of which can ultimately lead to 
production of the anaphylatoxin C5a (Klos et al., 2013; Markiewski and Lambris, 2007; 
Mukherji et al., 1986), one of the most potent inflammatory proteins known (el-Lati et al., 
1994).  Most of the canonical biological activities of C5a are thought to be mediated via the 
G-protein coupled C5aR1 (Guo and Ward, 2005).  Several studies suggest that complement 
C5a-C5aR1 signalling can promote tumour growth by sustaining chronic inflammation, with 
C5aR1 antagonism having anti-tumour effects in cervical, lung and ovarian cancer models 
(Corrales et al., 2012; Markiewski et al., 2008a; Markiewski et al., 2008b; Nunez-Cruz et al., 
2012).  However these studies suggest differing effects in different tumour types, possibly 
depending on the levels of C5a (Gunn et al, 2012).  Although the cross-talk between C5aR, 
MDSC and Tregs has been documented in mouse models of cervical, lung and lymphoma 
(Markiewski et al, 2008; Corrales et al 2012, Gunn et al, 2012), other mechanisms of action 
have been proposed in other tumour models (Kim et al, 2005; Nunez-Cruz et al, 2012).  Thus 
this thesis investigated possible mechanisms by which C5aR signalling acts on melanoma 
growth.  Moreover, despite emerging evidence that the alternative C5a receptor, C5aR2, can 
independently induce and modulate biological functions of C5a through β-arrestin signalling 
(Croker et al., 2014; Li et al., 2013), a role for this receptor, C5aR2, in tumour development 
has not been reported. 
The lack of effective/sustained therapies for melanoma, along with mounting evidence that 
C5aR1 signalling plays a role in tumour growth, led us to investigate the therapeutic potential 




the absence of reports investigating C5aR2 in tumourigenesis, the effects of C5aR1 and 
C5aR2 deficiency on development of B16 tumours were also compared.  The results 
demonstrate that whilst C5aR1 signalling is pro-tumourigenic, C5aR2 acts to limit tumour 
growth.  Overall, the data provide support for the premise that C5a receptor signalling is a 




3.2 EXPERIMENTAL OUTLINE 
To determine whether complement is activated in human melanoma tissue, human melanoma 
tissue arrays (US BioMax Inc, Rockville, MD) were immunostained for complement 
activation product C4d (Section 2.7).  
To investigate receptor expression, B16 melanoma cells and J774 macrophages (positive 
control) were cultured on coverslips and immunostained with antibodies specific for C5aR1 
and C5aR2 (Section 2.6).  Cell suspensions were immunostained with the same antibodies for 
FACS analysis (Section 2.11).  To determine whether cells are capable of activating other 
signalling pathways, cells were grown to approximately 70% confluence in T-25 culture 
flasks and treated with recombinant mouse C5a (mC5a; 10 nM) or antagonist (PMX53; 10 
μM) for various times, then cell lysates subjected to Western analysis for activated ERK or 
AKT (Section 2.8).  To determine whether C5aR activation stimulates proliferation of B16 
melanoma cells, cells were treated with C5a agonist EP54 (1μM) (or medium alone) for 48 
hours, then cell proliferation rates determined by MTT assay (Section 2.9). 
To investigate the role of C5aR1 signalling in melanoma growth, wild-type C57BL/6J mice 
were injected s.c. with B16 melanoma cells (2.5 x105 cells/mouse; as described in Section 
2.4) followed by daily s.c. injections of either C5aR1 antagonist AcF-[OPdChaWR] (PMX53; 
1 mg/kg/day) or vehicle only (saline) control, commencing once tumours became palpable 
(approx 7 days after injection); tumour areas were measured daily with Vernier callipers 
(Section 2.4).  Once the largest tumours reached 200 mm2 (approx day 14), mice were 
euthanized, tumour excised and weighed. 
In order to further investigate the role of C5aR1 and C5aR2 signalling in melanoma growth, 
female homozygous C5a receptor knockout (C5aR1 -/- and C5aR2 -/-, both on C57BL/6J 
background) or wild-type (C57BL/6J) mice were injected s.c. with B16 melanoma cells (2.5 
x105 cells/mouse; as described in Section 2.4). Once the largest tumours reached 200 mm2 
(approx day 14), mice were euthanized.  Blood from each mouse was collected by cardiac 
puncture, and tumours, draining (axillary and inguinal) lymph nodes, spleen and femurs (for 
bone marrow cells) removed for FACS analysis (Section 2.11).  Tumour tissue from some 
mice was OCT-embedded for cryosectioning (Section 2.5) and immunostaining (Section 2.6). 
Plasma and tumour tissue from other mice was snap frozen and protein extracted for 





3.3.1 Evidence for complement activation in human malignant melanoma tissue 
Complement activation products have previously been detected in tumour tissue including 
breast (Niculescu et al., 1992) and lung cancer (Ajona et al., 2013). To investigate whether 
complement is also activated in human melanoma tissue, melanoma tissue arrays were 
immunostained for the complement activation product C4d.  As shown in Figure 3.1, C4d 
was detected in melanoma tissue at higher levels than in normal skin.  Representative images 
illustrate high levels of C4d deposition in malignant melanoma stage II (Figure 3.1B), 
malignant melanoma stage III (Figure 3.1C), and lower levels in normal dermis adjacent to 
tumour (Figure 3.1D). Of 103 melanoma tissue biopsies examined, C4d staining was evident 
in 92.  However there was no correlation between C4d levels and stage of disease. 
Figure 3.1.  Immunohistochemical staining of human melanoma tissue array showing 
C4d deposition (AEC; red) (A).  Representative images show malignant melanoma stage 
II (B) and stage III (C), normal dermis adjacent to tumour (D) and staining with isotype 




3.3.2 C5aR1 antagonism inhibits melanoma growth 
Inhibition of C5aR1 using the cyclic hexapeptide antagonist AcF-[OPdChaWR] (PMX53; 
C5aR1A), developed by Taylor and co-workers (Finch et al., 1999) has previously been 
demonstrated to be effective at reducing tumour growth in mouse models of cervical 
(Markiewski et al., 2008a), lung (Corrales et al., 2012; Gu et al., 2013) ovarian (Nunez-Cruz 
et al., 2012) and metastatic breast cancer (Vadrevu et al., 2014).  We therefore first 
investigated whether pharmacological antagonism of C5a-C5aR1 signalling also has 
therapeutic effects in the B16 murine melanoma model.  For this experiment, B16 melanoma 
tumours were established in C57Bl/6J mice, and once tumours became palpable (approx. day 
7), mice were injected daily with PMX53 (1mg/kg/day).  As shown in Fig 3.2, the rate of 
tumour growth was significantly slowed in PMX53-treated mice (Fig 3.2A; p=0.0001, 
Permutation test), with excised tumour weight at day 14 reduced to 0.19 ±0.17 g compared 
with 0.44 ±0.22 g in the vehicle-treated controls (Fig 3.2B; p<0.0001). 
Figure 3.2. C5aR1 antagonism inhibits 
melanoma growth.  Tumour areas (A) 
measured daily in live mice from the time 
they become palpable, and excised 
tumour weight (B) following euthanasia 
on day 14 for wild-type C57BL6/J mice 
receiving vehicle (saline) or the C5aR1 
antagonist (PMX53; 1 mg/kg/ day s.c.) 
commencing day 7. Representative 
images (C) show tumours from mice 
treated with vehicle alone or C5aR1 
antagonist. Data expressed as mean ± SD 
from 3 independent experiments; n=7-
8/group. ** p<0.005 Permutation test; 





3.3.3 Complement C5a receptor expression by B16 melanoma cells in vitro and in vivo 
3.3.3.1 Immunofluorescence staining of B16 cells 
In order to understand the mechanism by which C5aR antagonism inhibits tumour growth, we 
first investigated whether C5a could act directly on tumour cells.  Immunostaining 
demonstrated that both C5a receptors (C5aR1 and C5aR2) (Fig 3.3) are expressed by cultured 
B16 cells, but at lower levels than found in J774 macrophages (positive control) which are 
known to express high levels of complement receptors (Chenoweth et al., 1982). The lack of 
staining with isotype controls shows lack of non-specific binding.  
Figure 3.3.  Complement receptor expression by mouse melanoma B16 cell lines.  
Fluorescence micrographs show expression of C5aR1 and C5aR2 (both FITC-labelled; 
green) by B16 melanoma cells compared with the control (J774 macrophages); nuclei are 
counterstained with Hoechst 33342 (blue).  Isotype control antibodies show lack of non-




3.3.3.2 FACS analysis of B16 cells 
The expression of C5aR1 receptor by cultured B16 melanoma cells was confirmed by flow 
cytometric (Fig 3.4A) and Western (Fig 3.4B) analysis.  Again expression was lower than for 
J774 macrophages.  C5aR2 expression was not examined due to lack of a suitable antibody 
for FACS and Western blotting. 
  
Figure 3.4.  Expression of C5aR1 byB16 melanoma cells. Flow cytometric analysis (A) 
shows C5aR1 (blue) expression by B16 melanoma cells compared with J774 macrophages 
(positive control) and cells labelled with isotype control antibody (red). Western blot (B) 




3.3.3.3 Immunohistochemical analysis of B16 melanoma tissue   
Importantly, C5aR1 expression was also demonstrated in B16 melanoma tissue from C5aR1-
/- mice (in which host cells lack C5aR1, but tumour cells express C5aR1) (Fig 3.5), excluding 
the possibility that receptor expression in tumour tissue is due solely to infiltrating host 
inflammatory cells.   
3.3.4 Functional evaluation of C5aR1 expressed by B16 melanoma  
Having demonstrated that B16 melanoma cells express C5aR1, we next determined whether 
these receptors are functionally coupled.  Previous studies have demonstrated that Gi protein-
coupled anaphylatoxin receptors can activate the MAP kinase pathway (Buhl et al., 1994; 
Norgauer et al., 1993; Rollins et al., 1991; Rousseau et al., 2006).  Given the importance of 
MAPK signalling to tumour cell proliferation (Beeram et al., 2005; Downward, 2003; Gollob 
et al., 2006; Pratilas and Solit, 2010; Santarpia et al., 2012), we next examined whether 
receptors expressed by B16 melanoma cells are capable of activating this pathway.  As 
shown in Fig. 3.6A, stimulation of B16 melanoma cells by recombinant mouse C5a (mC5a) 
activated p44/p42 ERK kinases at all time-points up to 1 hour, demonstrating that C5aR1 is 
functionally active in these cells.   
Figure 3.5.  C5aR1 expression by B16 melanoma tissue. Fluorescence micrographs 
show expression of C5aR1 (FITC; green) by B16 melanoma tissue grown in C57Bl/6J 
(wild-type) and C5aR1 knockout mice (C5aR1-/-); nuclei are counterstained with Hoechst 
33342 (blue). Scale bar = 25 μm. 




Since the MAPK pathway is known to regulate cellular processes such as cell proliferation 
and migration, we next determined the effect of C5a on these processes in B16 cells.  
However C5a had little or no effect on proliferation (Fig 3.6B) or cell migration (Fig 3.6C).  
Given the key role of C5a in immunity, and the fact that C5a receptors are expressed at high 
levels on inflammatory cells (Monk et al., 2007), this suggests that the anti-tumour effects of 
C5aR1 antagonism as shown above, may be indirect, via the immune system as shown by 






3.3.5 B16 melanoma growth is altered in C5a receptor-deficient mice 
3.3.5.1 C5aR1 deficiency significantly impairs B16 melanoma growth  
Although we showed that C5aR1 expressed by B16 cells is capable of signal activation, we 
were unable to demonstrate any significant effects of C5a on cell proliferation or migration.  
Thus we next used C5aR1-deficient mice to determine whether the anti-tumour effects of 
C5aR antagonism may be indirect (via effects on host cells).  In this case, the tumour-bearing 
mice are chimaeras, in which the host cells lack C5aR1, but the injected B16 melanoma cells 
are wild-type (ie expressing C5a receptors).  As shown in Fig 3.7A, tumour growth was 
markedly reduced in C5aR1-deficient mice (p<0.001, Permutation test).  Excised tumour 
weight at euthanasia (Fig 3.7B) was also significantly reduced in these mice (0.15 ± 0.12 g) 
compared with the wild-type controls (0.39 ± 0.29 g; p<0.0001, Mann Whitney test). 
  
Figure 3.7.  Tumour development is 
retarded in C5aR1-deficient mice. 
Tumour area (A) and excised weight at 
14 days post-tumour induction (B) in 
C57BL/6J (wild-type; WT) compared 
with C5aR1-deficient (C5aR1-/-) mice; 
images (C) show representative tumours 
from WT and C5aR1-/- mice. Data 
expressed as mean ± SD from 4 
independent experiments (n=8-
12/group);***P<0.001 Permutation test; 





3.3.5.2 C5aR2 deficiency leads to enhanced B16 melanoma growth  
C5aR2 is the alternate receptor for C5a, but a role for this receptor has not yet been reported 
in tumour growth.  Investigation of B16 melanoma growth in C5aR2-deficient mice showed 
that, in contrast to the C5aR1-/- mice, in which tumour growth was retarded, tumour growth 
was enhanced in the absence of C5aR2 (p<0.01; Fig 3.8A); excised tumour weight (0.21 ± 
0.16 g) was significantly larger than that for the wild-type controls (0.35 ± 0.19 g; p<0.05; 
Fig 3.8B).   
 
  
Figure 3.8.  Tumour growth is enhanced 
in C5aR2-deficient mice. Tumour area (A) 
and excised weight 14 days post-tumour 
induction (B) in C57BL/6J (WT) compared 
with C5aR2 deficient (C5aR2-/-)  mice.  
Images (C) show representative tumours 
from WT and C5aR2-/-mice. Data 
expressed as mean ± SD from 3 
independent experiments (n=6-8 
mice/group); **P<0.01 Permutation test; 




3.3.5.3 C5aR1 antagonist treatment of C5aR1-/- mice does not induce further tumour 
reduction of B16 melanoma growth  
We next determined whether the effects of the C5aR1 antagonist (PMX53) are solely due to 
effects on the host immune system, or whether it also affects tumour cells directly. To do this, 
we investigated if there was any additional therapeutic effect of C5aR1 antagonism on 
melanoma growth in C5aR1-/-mice.  As in previous experiments, tumour growth was 
significantly reduced in both C5aR1-/- and wild-type mice treated with C5aR1 antagonist 
(Fig 3.9).  However, daily treatment (from day 7) of tumour-bearing C5aR1-/- mice with 
C5aR1 antagonist had no additional effect on tumour growth.  Since the tumour cells express 
C5a receptors, this result supports the premise that the tumour promoting effects of C5a are 
mediated via effects on the host immune system, not by any direct effect on the tumour cells 
themselves. 
  
Figure 3.9.  Effect of C5aR1 antagonism on growth of established B16 tumours in 
wild type and C5aR1 deficient mice.  Tumour areas (A) and weight of excised tumours 
(B) from WT and C5aR-/- mice treated from day 7 with either saline (Veh) or PMX53 
(C5aR1A; 1mg/kg/day). Data expressed as mean ± SD (n= 7/group); *p<0.05, **p<0.01, 
***p<0.0005 compared with vehicle-treated wild-type control mice, Permutation test (A) 




3.3.6 Effect of C5aR inhibition on tumour infiltrating leukocytes  
3.3.6.1 Immunofluorescence staining  
The demonstration that the growth of C5aR-expressing B16 melanoma is retarded in mice 
lacking C5aR1 indicated that the observed anti-tumour effects are indirect, likely via the host 
immune system.  Thus we assessed the contribution of immune cells to tumour tissue.  
Immunofluorescence staining of subcutaneous B16 melanoma tissue demonstrated the 
presence of infiltrating leukocytes (CD45+ cells).  In comparison to wild-type mice, tumour 
tissue from C5aR1-/- mice contained increased numbers of neutrophils (Ly6G+; green, 
second panel) and T lymphocytes (CD3+; green, fourth panel); macrophages (F4/80+; red) 
were also present (Fig 3.10).  
3.3.6.2 Flow cytometric analysis of tumour infiltrating leukocytes 
To investigate the effect of C5aR deficiency/inhibition on tumour infiltrating leukocyte 
populations, tumour tissues from wild-type (untreated or C5aR1 antagonist-treated) and 
C5aR-deficient mice were harvested on day 14 and used for FACS analysis (Figure 3.11).  
Tumour tissue from vehicle-treated wild-type mice showed 2.25 ± 0.87 % of all cells were 
Figure 3.10.  Leukocyte infiltration of B16 melanoma tissue.  Immunostaining of B16 
tumours from WT and C5aR1-/- mice shows CD45+ cells (green, first panel) within tumour tissue.  
Some of these cells stain positive for macrophages (F4/80+; red, second panel), neutrophils 
(Ly6G+; green, second panel) and T lymphocytes (CD3+; green, fourth panel). Nuclei are stained 
with Hoechst 33342 (blue); scale bar = 20µm. 






leukocytes (CD45+).  C5aR antagonist treatment of established tumours (commencing day 7 
after tumour induction) resulted in a slight increase in leukocyte (CD45+) infiltration (2.66 ± 
0.92 % of total cells), although this was not significantly different from the vehicle-treated 
control.  However, tumours from C5aR1-deficient mice contained a significantly higher 
proportion of tumour infiltrating leukocytes (5.34 ± 3.41% of total cells; p=0.031).  While the 
proportion of neutrophils (CD11b+ Ly6G+) was similar in all groups, the percentage of 
myeloid derived suppressor cells (CD11b+GR1+) was significantly reduced in tumours from 
C5aR1-/- (2.48 ± 0.87% of total leukocytes; p=0.008) and C5aR1 antagonist treated mice 
(2.77 ± 0.8%; p=0.03) compared with vehicle-treated wild-type mice (5.52 ± 2.45 %), a result 
that is in accord with previous reports (Corrales et al., 2012; Gunn et al., 2012; Markiewski et 
al., 2008a).  Although the percentage of macrophages was not altered in tumours from 
C5aR1-/-, it was significantly reduced in C5aR1 antagonist-treated mice (4.23 ± 1.09 % 
compared to 7.33 ± 3.54 % for vehicle-treated controls; p<0.02).  There was also a significant 
increase in tumour-infiltrating CD3+ cells (T lymphocytes) in C5aR1-/- (7.13 ± 1.78% of 
total leukocytes; p=0.01) compared to wild-type mice (4.92 ± 1.24%); C5aR antagonist 
treated mice also showed a slight increase in CD3+ cells (6.3 ± 1.46%) compared to the 
vehicle-treated group (4.92 ± 1.24%), but this was not significant (p=0.09).  
The demonstration that T lymphocyte infiltration of tumours was increased in C5aR1-/- mice 
supports the suggestion by Markiewski and co-workers (2008) that C5a acts to promote 
MDSCs, which in turn inhibit cytotoxic T cell responses.  Given that C5a has been reported 
to regulate the differentiation of T cell subsets (Fang et al., 2009; Hashimoto et al., 2010; 
Weaver et al., 2010), we investigated T lymphocyte subsets and showed a significantly higher 
percentage of tumour-infiltrating CD4+ cells in C5aR1-/- (3.98 ± 2.28% of total leukocytes; 
p=0.01) compared with vehicle-treated wild type (1.86 ± 0.87%), but no significant 
difference in C5aR1 antagonist-treated (2.62 ± 1.01%) mice. However, in contrast to 
Markiewski et al (2008) we found that CD8+ cells were significantly reduced in C5aR1-
antagonist treated mice (1.76 ± 0.58 % of total leukocytes; p=0.04) compared with vehicle-




3.3.6.3 Flow cytometric comparison of tumour-infiltrating leukocyte populations from 
C5aR1-/- and C5aR2-/- mice. 
Since C5aR2 inhibition was shown to promote melanoma growth, we next compared tumour 
infiltrating leukocyte populations from C5aR2-/- mice with those from C5aR1-/- and WT 
mice.  In contrast to C5aR1-deficient mice, tumour infiltrating leukocyte populations in 
C5aR2-deficient mice were not significantly different from those of their wild-type 
counterparts (Figure 3.12).   
Figure 3.11.  C5aR signalling influences tumour infiltrating leukocyte populations.  
Representative flow cytometric plots show leukocyte sub-populations in B16 melanoma 
tissue from WT, C5aR1-/- and WT mice treated daily with C5aR1A (1mg/kg/day), 
commencing from the time tumours became palpable (day 7 after injection of B16 cells).  
Data is expressed as % positive cells (mean ± SD; n=9/group); results representative of 2 
independent experiments; *p< 0.05, **p<0.001 compared with the WT control; Kruskal 




3.3.6.4 Leukocyte populations in other tissues  
Since significant alterations in tumour-infiltrating leukocyte populations were observed in 
C5aR1-/- mice, we next examined leukocyte populations in blood, spleen and bone marrow 
(the major leukocyte reservoirs) and draining lymph nodes (the site of T cell 
maturation/activation) from healthy mice (without tumours) and tumour-bearing mice.  
Leukocyte populations in these tissues were compared with those within tumour tissue.  
Analysis of blood from healthy mice (Figure 3.13A) showed differences in frequencies of 
immune cell populations in C5aR1-/- compared with wild-type mice.  Although the 
percentages of monocytes (CD11b+ Ly6C+), MDSCs (CD11b+GR1+) and macrophages 
(F480+) were slightly, but not significantly, higher in healthy C5aR1-/- mice, neutrophils 
(CD11b+ Ly6G+; 10.7 ± 4.98%) were significantly higher than in their wild-type counterparts 
(5.5 ± 2.4% of total leukocytes; P=0.02).  Conversely the percentage of total T lymphocytes 
(CD3+) was significantly lower in healthy C5aR1-/- mice (10.84 ± 1.17%) compared with 
Figure 3.12.  Flow cytometric analysis of tumour infiltrating leukocyte populations 
from C5aR1- and C5aR2- deficient mice.  Representative flow cytometric plots show 
leukocyte sub-populations in B16 melanoma tissue from WT, C5aR1-/- and C5aR2-/- 
mice. Data are expressed as % positive cells (mean ± SD; n=6/group); results 
representative of 2 independent experiments; *p< 0.05, **p<0.01, ***p<0.001 compared 




wild type mice (25 ± 5.2%; P=0.0002).  CD4+ and CD8+ lymphocyte populations were both 
significantly lower, comprising 3.68 ± 0.54% and 5.3 ± 0.9% respectively compared with 
13.9 ± 3.4% (P=0.0002) and 9.5 ± 2.1% (P=0.0002) in wild-type mice.  However, 
examination of CD4+ T cell subsets showed significantly higher percentages of Tregs 
(CD25+FoxP3+; P=0.02), Th1 (IFNγ+; P=0.0006), Th2 (IL4+; P=0.0006) and Th17 (IL17+; 
P=0.003) cells in healthy C5aR1-/- mice.   
Leukocyte populations in blood of tumour bearing C5aR-/- mice showed a similar trend to 
their healthy counterparts (compare Fig 3.13 panels A and B), with the percentage monocytes 
(CD11b+ Ly6C+ P=0.005), neutrophils CD11b+ Ly6G+ (P=0.0012) and MDSCs 
(CD11b+GR1+ 17.8± 3.01% of total leukocytes; P=0.0002) higher than in tumour bearing 
wild-type mice.  While total T lymphocytes (CD3+), CD4+ and CD8+ T lymphocyte 
populations in the circulation were significantly lower, all CD4+ subsets were significantly 
higher, suggesting increased CD4+ cell activation.  It is interesting to note that, despite 
significantly lower levels of T cells in blood of C5aR1-/- mice compared with wild-type, the 
percentages of tumour infiltrating T cells (CD3+, CD4+) were significantly increased.  
Moreover, the proportions of tumour infiltrating Tregs were significantly reduced and Th2 
cells significantly increased. 
These results suggest an inverse relationship between leukocyte populations in the blood and 
tumour tissue.  Whereas C5aR1-deficient mice (with or without tumours) have higher 
proportions of myeloid cell populations and fewer T lymphocytes, the proportions of 
monocytes and neutrophils within tumour tissue were similar, and the percentage of MDSCs 
significantly lower (5.4 ± 2.5% of total leukocyte; P=0.007) compared to wild-type mice 
(11.4 ± 5.6% of total cells).  Importantly, total (CD3+) T lymphocyte infiltration of tumour 
tissue was significantly higher in C5aR1-/- (5.9 ± 1.4% of total leukocytes) compared with 
wild type (3.3 ± 0.7%; p=0.0006) mice.  CD4+ cells were also significantly higher (P=0.007) 
but CD8+ cells were not significantly different.  Analysis of CD4+ T cell subsets showed the 
proportion of tumour infiltrating Tregs was significantly lower in tumours from C5aR1-/- 
mice (P=0.0009), whereas Th2 cells were significantly higher (4.5 ± 2.3% of CD4+; P=0.02) 
compared to wild type (1.9 ± 0.8% of CD4+) mice.  Although Th1 and Th17 cells were 








FACS analysis of draining (axillary and inguinal) lymph nodes (Figure 3.14) showed similar 
results to blood (Figure 3.13), with the percentage of monocytes, neutrophils and 
macrophages slightly (but not significantly) higher, but the percentage MDSCs significantly 
higher (P=0.007) in healthy C5aR1-/- compared with wild-type mice.  In contrast to blood, 
total T lymphocytes (CD3+) were similar in both groups, as were CD8+ cells.  CD4+ cells 
were reduced, but unlike blood in which all CD4+ subsets were significantly higher, only Th1 
cells were higher in the lymph nodes of C5aR-deficient mice.  Lymph nodes from tumour-
bearing mice showed similar trends, but with neutrophils, MDSC and CD4+ subsets (Treg, 
Th2 and Th17) all significantly higher in C5aR1-/- mice. 
 
 
Figure 3.13.  Flow cytometric analysis of blood leukocyte populations from mice with 
and without tumours and comparison with tumour infiltrating populations. 
Representative flow cytometric plots show leukocyte sub-populations in blood from WT 
and C5aR1-/- mice without tumours (NT-WT, NT-C5aR1-/-; A), or bearing B16 
melanoma (T-WT, T-C5aR1-/-; B) compared with tumour tissue from WT and C5aR1-/-
mice (C). Data are expressed as % positive cells (mean ± SD; n=8/group); *p< 0.05, 










Examination of leukocyte populations in spleen showed significantly higher percentages of 
monocytes, neutrophils and MDSCs in healthy C5aR1-/- mice compared to wild type controls 
(Fig 3.15).  Whereas the proportions of CD3+, CD4+ and CD8+ T cells were significantly 
lower, CD4+ subsets (Th1, Th2 and Th17) were all significantly higher.  Spleens from tumour 
bearing mice showed a similar pattern to their healthy counterparts, with C5aR-/- mice 
exhibiting higher percentages of monocytes, neutrophils and MDSC, significantly reduced 
CD8+ T cells.  As for lymph nodes the proportions of CD4+ subsets (Tregs, Th1, Th2 and 
Th17) were higher in C5aR-/- mice, possibly suggesting increased activation of CD4+ T cells.   
Figure 3.14.  Flow cytometric analysis of draining lymph node leukocyte populations 
from mice with and without tumours compared with tumour infiltrating populations. 
Representative flow cytometric plots show leukocyte sub-populations in draining lymph 
nodes from WT and C5aR1-/- mice without tumours (NT-WT, NT-C5aR1-/-; A) or 
bearing B16 melanoma (T-WT, T-C5aR1-/-; B) compared with tumour tissue from WT 
and C5aR1-/- mice (C). Data is expressed as % positive cells (mean ± SD; n=8/group); 











3.3.7 Effect of C5aR deficiency on cytokine/chemokine expression 
C5a is a potent chemoattractant for leukocytes, but also induces the expression of pro-
inflammatory cytokines such as IL-6 and TNF-α (Montz et al., 1991).  Tumour tissue is also 
known to express a range of chemokines and their receptors (Conti and Rollins, 2004).  In 
order to gain insight into how C5a regulates changes in tumour infiltrating populations, we 
investigated cytokine (Fig 3.16A, B) and chemokine (Fig 3.16C, D) expression in tumour 
tissue extracts and plasma from wild-type and C5aR-deficient mice.  Based on our FACS 
findings, we chose chemokines previously reported to regulate tumour infiltrating leukocyte 
populations. Except for IFN-γ which was significantly increased in plasma from C5aR1-
deficient mice, and IL12p40 which was significantly reduced in tumour tissue from these 
mice, expression of other cytokines was not altered in either tumour tissue or plasma from 
Figure 3.15.  Flow cytometric analysis of leukocyte populations in spleens from mice 
with and without tumours compared with tumour infiltrating populations. 
Representative flow cytometric plots show leukocyte sub-populations in spleen from wild 
type (C57BL/6J) mice, C5aR1 deficient mice without tumour (NT-WT, NT-C5aR1-/-; A), 
or bearing B16 melanoma (T-WT, T-C5aR1-/-; B) compared with tumour tissue from wild 
type (C57BL/6J) mice and C5aR1 deficient mice (WT, C5aR1-/-; C).  Data are expressed 





C5aR1- or C5aR2-knockout compared with their wild-type counterparts (Fig 3.16A, B).  
Analysis of chemokine expression revealed significant reductions in MCP-1 (CCL2; 
P=0.0003), MIP1α (CCL3; P=0.03), MIP1β (CCL4) (P=0.03), MIP2 (CXCL2; P=0.03) and 
RANTES (CCL5; P=0.001) in tumour tissue from C5aR1-/- mice; CCL2, CXCL1 and 
CXCL2 were significantly lower in tumours from C5aR2-/- mice (Fig 3.16C).  C5aR2-/- 





Figure 3.16. Influence of C5aR deficiency on cytokine and chemokine expression.  
Cytokine (A, B) and chemokine (C, D) levels in tumour tissue (A, B) and plasma (C, D) 
from WT (●), C5aR1-/- (○) and C5aR2-/- () mice.  Data expressed as pg/ml (for 
plasma) or pg/mg (for tumour tissue) (mean ± SD, n=6-8/group); *p< 0.05, **p<0.01, 







The complement system is a key component of the innate immune system, and the activation 
product anaphylatoxin C5a is a potent chemoattractant and pro-inflammatory mediator 
responsible for mediating many of the effects of the immune system (Manthey et al., 2009).  
The present study implicates C5a-C5aR1 signalling for a role in promoting melanoma 
growth.  In accord with previous studies in murine models of cervical, lung and ovarian 
cancer (Corrales et al., 2012; Markiewski et al., 2008b; Nunez-Cruz et al., 2012), the results 
show that treatment of mice with the C5aR1 antagonist (PMX53) developed at the University 
of Queensland (Finch et al., 1997) inhibits the growth of primary B16 melanoma.  Similar 
anti-tumour effects were observed in mice lacking C5aR1, with tumour initiation and growth 
significantly slower than in their wild-type counterparts.  Importantly, this study is the first to 
show that tumour growth is increased in mice lacking the non-signalling receptor, C5aR2, a 
result in accord with the postulated role of C5aR2 as an anti-inflammatory modulator of 
C5aR1 activity (Bamberg et al., 2010; Scola et al., 2009).  
Investigation of the mechanisms by which C5a acts on tumour growth showed that B16 
melanoma cells express C5a receptors C5aR1 and C5aR2, albeit at lower levels than J774 
macrophages. Furthermore, C5aR expressed by melanoma cells is functional, with C5a 
stimulation leading to signal activation via MAPK pathways, thus indicating that direct 
effects of C5a on B16 melanoma cells are possible.  Similar to the current findings, 
Hawksworth and co-workers (2014) have recently demonstrated that human embryonic stem 
cells respond to C5a through ERK and AKT pathways, despite these cells having no 
detectable calcium mobilisation (et al., 2014).  However, our inability to demonstrate any 
effect of C5a on B16 cell proliferation or migration suggests that the anti-tumour effects of 
C5aR1 antagonism are predominantly indirect, via the host immune system.  This possibility 
is supported by the demonstration that wild-type (C5aR-expressing) B16 melanomas grow 
more slowly in C5aR1-deficient mice.  Hence this study focussed on how C5a-C5aR 
signalling influences immune cell populations in tumour-bearing mice.   
Examination of leukocyte populations in healthy mice showed that C5aR1 deficiency is 
associated with intrinsic differences in circulating leukocyte populations.  Healthy and 
tumour-bearing mice showed similar patterns, with higher percentages of myeloid cells but 




compared with their wild-type counterparts. Interestingly the proportions of CD4+ 
subpopulations (Treg, Th1, Th2 and Th17) were increased in C5aR1-/- mice. However 
tumour-infiltrating leukocyte populations showed a different pattern. As previously 
demonstrated in other cancer models (Corrales et al., 2012; Markiewski et al., 2008a), tumour 
infiltrating MDSC and macrophages were significantly reduced in C5aR1-deficient mice. 
MDSCs are potent inhibitors of anti-tumour immunity in vivo, inducing Tregs which down-
regulate cell mediated immunity and promote tolerance to tumour antigens (Serafini et al., 
2008). In addition to their presence within tumours, MDSCs accumulate in peripheral blood, 
bone marrow, spleen and lymph nodes (Haile et al., 2008; Kusmartsev et al., 2005; Marigo et 
al., 2008; Serafini et al., 2008; Sinha et al., 2008).   
Although the present study found that C5aR1-/- mice had reduced tumour infiltrating MDSC, 
these mice (healthy and tumour-bearing) had higher percentages of MDSC in blood, spleen 
and lymph nodes than their wild-type counterparts, suggesting that the infiltration of these 
cells into the tumour may be regulated by C5a, a strong chemoattractant for myeloid cells 
(neutrophils, monocytes and macrophages) (Guo and Ward, 2005). We also demonstrated the 
down-regulation of several chemokines within the tumour microenvironment of C5aR-
deficient mice, including MCP-1 (CCL2), MIP1β (CCL4) and RANTES (CCL5) which are 
known to regulate the movement of MDSC and maintain their suppressive activity (Boelte et 
al., 2011; Sevko and Umansky, 2013; Zollo et al., 2012). In particular, CCL2 and its 
receptors CCR2 and CCR4 have been reported to be responsible for the accumulation of 
monocytic MDSCs in melanoma and prostate cancer (Lesokhin et al., 2012; Zhang et al., 
2010; Zollo et al., 2012), and high levels of CCL2 expression have been associated with poor 
prognosis in human mammary carcinoma (Sato et al., 1995; Ueno et al., 2000; Valkovic et 
al., 2002).  Others have reported a role for CCL3 and CCL5 in regulating the migration of 
monocytic MDSC (Connolly et al., 2010; Gama et al., 2012; Sawanobori et al., 2008).  The 
presence of macrophages in melanoma is also positively correlated with aggressiveness of 
disease (Varney et al., 2005), and the lower levels of CCL2, CCL3 and CCL4 may also 
explain the reduction in tumour associated macrophages (Roca et al., 2009; Solinas et al., 
2009) in C5aR-deficient mice.  Although not investigated in the present study, tumour 
associated macrophages and MDSC are capable of promoting angiogenesis (Leek et al., 




al., 2004), and thus higher expression of CCL2 in melanoma tissue from wild-type mice may 
contribute to increased angiogenesis (Boelte et al., 2011) and hence enhanced tumour growth.  
In contrast to Markiewski and co-workers who showed that the tumour promoting effects are 
due to inhibition of CD8+ cytotoxic T cells, the present study suggests that the effects of C5a 
on melanoma growth are due to changes in tumour infiltrating CD4+ T cell sub-populations.  
Specifically tumours from C5aR1-/- mice showed a significantly lower percentage of Tregs 
but increased Th2 cells.  This result is in contrast to previous reports showing that C5aR 
signalling reduces Treg function (Kwan et al., 2013; Strainic et al., 2013), but in accord with 
the findings of Gunn and co-workers (2012) that C5a promotes Treg differentiation in vitro 
and splenic Treg cells were significantly increased in the presence of high C5a levels.  
Although Corrales et al (2012) found no effect of C5aR1 antagonism on CD4+, CD8+ or Treg 
cells, key immunosuppressive molecules associated with Treg activity, including CTLA-4, 
IL-6, IL-10 and ARG1, were down-regulated.  Similar results were obtained by Vadrevu et al 
(2014)who showed in a murine model of metastatic breast cancer, that C5aR1 signalling 
suppresses T-cell responses in the lungs via recruitment of MDSCs and generation of Treg 
cells. In contrast to our results, this group showed that C5aR1 blockade led to increased 
recruitment of both CD4+ and CD8+ T cells and induction of Th1/Tc1-biased T-cell 
responses.  CD8+ T cells are generally thought to be responsible for cytotoxic anti-tumour 
responses, whereas Th2-mediated immune responses favour tumour growth through 
promoting angiogenesis and mediating immunosuppression (Ellyard et al., 2007; Nishimura 
et al., 1999). However, CD4+ Th2 have been reported to play an important role in the 
response to MHC class I negative tumours which are resistant to CD8+ cytotoxic T 
lymphocytes (Mattes and Foster, 2003).  Moreover the Th2 response has been shown to be 
important for immunity against B16 melanoma (Fang et al., 2009).  Thus, in the B16 
melanoma model, the up-regulation of Th2 cells (and concomitant reduction in CD8+ T cells) 
in the absence of C5aR1 signalling may be consistent with an effective anti-tumour response. 
The demonstration that expression of CCR5 ligands CCL3, CCL4 and CCL5 are reduced in 
tumours from C5aR1-, but not C5aR2-deficient mice suggests that CCR5 may be an 
important contributor to the effects of C5aR1 on the anti-tumour immune response.  CCR5 is 
expressed on various cell populations including macrophages, dendritic cells and memory T 
cells (Rottman et al., 1997).  CCR5 and its ligands are also expressed by a range of tumours 




pancreatic cancers (Vaday et al., 2006).  There is evidence that the CCL5/CCR5 axis is 
associated with melanoma progression due to increased levels of immunosuppressive cells.  
CCR5 deficiency has been shown to cause apoptosis of melanoma cells (Song et al., 2012), 
while melanoma growth is delayed in CCR5-deficient mice.  CCL5 is a chemoattractant for T 
cells, macrophages, eosinophils and basophils (Aldinucci and Colombatti, 2014).  CCL5 
plays a key role in inducing apoptosis of tumour infiltrated lymphocytes (Mellado et al., 
2001), with activity up-regulated by the other CCR5 ligands, CCL3 and CCL4.  Recently, 
Schlecker et al. (2012) demonstrated in a mouse model of melanoma, that tumour-infiltrating 
monocytic-MDSCs directly attract Tregs via CCR5 and that intra-tumoural injection of CCL4 
or CCL5 increased tumour-infiltrating Tregs. 
In summary, the results presented here suggest the potential of C5aR signalling as a 
therapeutic target for melanoma.  In addition to demonstrating a role for C5aR1 signalling in 
promoting the growth of murine melanoma, this thesis provides the first evidence for a role of 
the alternate receptor C5aR2 in modulating the effects of C5a on tumour growth.  In accord 
with previous studies in other tumour types, the results suggest that C5a mediates its effects 
via the immune system, with tumour infiltrating leukocyte populations altered in C5aR1-
deficient mice.  Although healthy C5aR-deficient mice are shown to have altered circulating 
leukocyte populations compared with their wild-type counterparts, the results suggest that 
leukocyte infiltration into the tumour is tightly regulated – either directly by C5a, or 
indirectly by other chemokines within the tumour microenvironment.   
Although like previous studies, this study demonstrates a tumour promoting role for C5a, 
further research is required to fully elucidate the mechanisms by which C5a acts.  Clearly 
further investigations are required to determine whether the observed changes in leukocyte 
populations reflect changes in the anti-tumour response, and whether similar mechanisms 
apply in human melanoma and other cancers.  Research to date suggests that C5a has 
different effects, depending on the tumour type, possibly due to differences in the 
immunogenicity of the different tumours, the type of response mounted, the strain of mice 
used and the levels of C5a present.  Indeed Gunn et al (2012) showed that the effect of C5a is 
concentration-dependent, with high levels promoting tumour growth by accumulation of 
neutrophilic (CD11b+GR1+) MDSC and reduction of the anti-tumour CD4+ and CD8+ T cell 




increased IFN γ producing CD4+ and CD8+ T cells in spleen and tumour draining lymph 
nodes.  These different effects highlight the fact that cancers are many different diseases, with 
different responses dependent on tumour type, the immune competence of the host and levels 
of complement activation in the tumour microenvironment. Further research is therefore 













THE COMPLEMENT C3A RECEPTOR 
CONTRIBUTES TO MELANOMA 
TUMOURIGENESIS BY INHIBITING 
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An essential part of the innate immune system, the complement system is comprised of 
plasma and membrane-bound proteins whose overall function is to regulate inflammation, 
facilitate immune defense mechanisms and maintain tissue homeostasis (Ricklin et al., 2010).  
Chapter 3 of this thesis demonstrated a tumour-promoting role for the complement activation 
product C5a in murine melanoma.  In addition to C5a, complement activation leads to the 
production of another peptide, C3a, which is less well studied, but generally thought to have 
similar effects (Klos et al., 2013). This simplistic view of C3a however has been challenged 
recently (Coulthard and Woodruff, 2015).   
Up-regulated levels of serum C3a have been reported in many cancers including breast, 
colorectal and oesophageal cancer (Maher et al., 2011; Medina-Echeverz et al., 2014), and 
gene expression data identifies the up-regulation of C3a receptor (C3aR) by some tumours, 
including melanoma (Xu et al., 2008).  Despite the evidence for C3a and C3aR expression by 
tumour tissue, the majority of studies to date have focused on the role of C5a (Corrales et al., 
2012; Gunn et al., 2012; Kim et al., 2005; Markiewski et al., 2008a; Nunez-Cruz et al., 2012).  
Thus, the current study used murine models of melanoma and colonic carcinoma to determine 
whether C3aR, like C5aR1 and C5aR2, also plays a role in tumourigenesis. 
C3aR is expressed by cells of myeloid origin (including neutrophils, mast cells, monocytes, 
macrophages and dendritic cells) as well as non-immune cells in lung, liver, muscle and other 
tissues.  Activation of C3aR can induce both pro- and anti-inflammatory effects, depending 
on the cell type and disease context (Coulthard and Woodruff, 2015). This Chapter explored 
the role of C3aR signalling in melanoma growth and regulation of leukocyte populations in 
the tumour microenvironment.  The results demonstrate that development and growth of 
syngeneic primary B16 and SM1WT1 (BRAFV600E mutant) murine melanomas are retarded 
in the absence of C3aR signalling, and that the anti-tumour effects of C3aR inhibition are 
linked to increased tumour infiltration by neutrophils and enhancement of the adaptive T-cell 
anti-tumour response.  Similar protective effects of C3aR deficiency are demonstrated in a 
colorectal cancer model.  These results suggest the potential of C3aR as a novel therapeutic 





4.2 EXPERIMENTAL OUTLINE 
To investigate the role of C3aR signalling in melanoma growth, C3a receptor knockout 
(C3aR -/-) or wild-type (WT; C57BL/6J) mice were injected s.c. with murine B16-F0 
melanoma (2.5 x105 cells/mouse) or BRAFV600E mutant SM1WT1 melanoma cells (2x106 
cells/mouse) (Section 2.4). For some experiments, C57BL/6J mice received daily injections 
of either C3aR antagonist (SB290157; 1mg/kg/day i.p.), C5aR1 antagonist (PMX53; 
1mg/kg/day s.c.) or vehicle only (0.9% saline or 5% glucose solution) control, commencing 
once tumours became palpable (approx. day 7 after tumour cell injection).  For most 
experiments, mice were euthanized at day 14 (or once the largest tumour reached an area of 
approx. 200mm2), blood was collected by cardiac puncture, tumours, spleen, draining lymph 
nodes (inguinal, axillary and brachial) and femurs excised for immunostaining (Section 2.6) 
or FACS (Section 2.11); tumours were weighed.  For ‘survival’ studies (Section 2.4), the time 
taken for each tumour to reach a pre-determined size (150 mm2) was recorded, then mice 
euthanized. 
To investigate receptor expression, human (MM608, MM370 and MM649) murine (B16-F0) 
melanoma and J774 macrophages (positive control) cultured on coverslips or OCT-embedded 
tumour sections were incubated with antibodies specific for human and mouse C3aR 
(Bachem, Bubendorf, Switzerland) followed by FITC conjugated secondary antibodies 
(Section 2.6).  Cell suspensions stained with the same antibodies were analysed by flow 
cytometry (Section 2.11).  To determine whether these receptors are capable of signal 
activation, B16 cells were treated with recombinant human C3a (10nM) or the selective 
mouse C3aR agonist WWGKKYRASKLGLAR (Proctor et al., 2009; Wu et al., 2013) for the 
times indicated in the experiment, then cell lysates subjected to Western analysis for 
activation of ERK or AKT (Section 2.8).  
To investigate the effect of C3aR agonist on B16 migration, cells were seeded at confluence 
(2x105 cells/cm2) into a 24 well plate, adhered overnight and then confluent monolayers 
scratched with a pipette tip before being treated for 24 hours with C3aR agonist (10-6 mol/L); 
control wells were incubated with medium alone or containing 5% FCS.  Migration was 
quantified by measuring cell-free areas at 0 and 24 hours using Image-J software (Section 
2.10). To investigate the effect of neutrophil depletion, WT and C3aR-/- mice were injected 




(Daley et al., 2008) or isotype control (rat IgG2a, 2A3) 24 hours prior to s.c.. injection of B16 
cells, and then every 3 days until the largest tumour reached 200mm3 (Section 2.4). Mice 
were then euthanized, and blood and tumour tissue removed and weighed.  
To further investigate the role of C3aR signalling in melanoma growth, tissue sections were 
also incubated with antibodies to leukocyte populations (Section 2.6).  Single cell 
suspensions of blood, tumour, spleen, lymph node and bone marrow cell were prepared for 
FACS analysis (Section 2.11). Protein extracted from snap frozen tumour and plasma tissues 
from other mice used for multiplex ELISA for a panel of chemokine/ cytokines (Section 
2.12).   
To determine whether C3aR signalling contributes to other tumour types, C57BL/6J mice 
were injected with MC38 colon carcinoma (1x106 cells/mouse), and tumour growth 
monitored as above.  
To determine the relevance to human cancer, neutrophil infiltration in human tissue was 
examined by staining human melanoma tissue arrays (US BioMax Inc, Rockville, MD) for 







4.3.1 C3a-C3aR signalling contributes to melanoma development and growth     
To determine whether C3a-C3aR signalling influences melanoma development and growth, 
we first compared the growth of s.c. implanted B16.F0 melanoma cells in C3aR-deficient 
(C3aR-/-) and wild-type (WT) C57Bl/6J mice. The rate of tumour growth in C3aR-/- mice 
was significantly retarded compared with WT mice (Fig 4.1A). Analysis of excised tumour 
weight at termination (day 14) confirmed that tumours were markedly smaller (23% of 
control) in C3aR-/- mice (Fig 4.1B, C).  Further, survival of C3aR-/- mice (i.e. euthanasia 
once tumours reached the pre-determined size of 150 mm2) was increased by 70% to 26.6 ± 
1.4 days, compared with 15.7 ± 0.7 days for the WT controls (Fig 4.1D).  These results 
suggest that host C3aR signalling promotes B16 tumour growth. 
4.3.2 Effect of combined C3aR/C5aR1 blockade on melanoma growth 
Since the downstream activation product C5a has been demonstrated to promote tumour 
growth (Corrales et al., 2012; Gunn et al., 2012; Markiewski et al., 2008a), we next 
investigated whether the tumour inhibitory effects observed in C3aR-/- mice could be 
augmented by C5a receptor (C5aR1) antagonism.  For this experiment, melanomas were 
induced in WT and C3aR-/- mice. Once tumours became palpable (day 8), mice were 
administered daily s.c. injections of C5aR1 antagonist (C5aR1A; PMX53) or vehicle alone.  
As previously shown in murine tumour models (Corrales et al., 2012; Gunn et al., 2012; 
Markiewski et al., 2008a) including B16 melanoma (Chapter 3), C5aR1 antagonism inhibited 
melanoma growth in WT mice (Fig 4.1E, F).  However, the reduction in tumour growth 
observed in C3aR-/- mice was not augmented by C5aR1 inhibition, indicating that the 
contribution of C3aR signalling to melanoma growth is at least as potent as C5aR1 signalling, 





   
  
Figure 4.1. C3aR deficiency retards B16 melanoma growth. Tumour area (A) and 
excised weight (B) 14 days post-tumour induction in C57BL/6J (wild-type; WT ●) and 
C3aR deficient (C3aR-/- ) mice (data expressed as mean ± SD from 4 independent 
experiments; n=8/group). Photographs (C) show representative tumours from mice WT 
and C3aR-/- mice. Kaplan-Meier curve (D) shows increased survival of C3aR-/- compared 
with WT mice; the terminal event is euthanasia once tumours reach maximal size 
(n=11/group). Tumour areas (E) and weight (F) of excised tumours from WT or C3aR-/- 
mice treated from day 7 with either saline (vehicle; WT ●, C3aR-/-) or C5aR antagonist, 
PMX53 (1mg/kg/day; WT , C3aR-/-) (mean ± SD n= 7/group); **p<0.01, 
***p<0.0005, ****p<0.0001, Permutation test (A and B), log-rank (Mantel-Cox) test (D), 
Mann-Whitney test (E) and Kruskal Wallis test followed by Dunn’s multiple comparisons 





4.3.3 C3aR blockade inhibits the growth of established primary melanoma  
The potent anti-tumour results in the C3aR-/- mice prompted us to determine the potential of 
C3aR therapeutic inhibition.  We therefore next investigated the therapeutic potential of a 
C3aR antagonist (C3aRA; SB290157) on the growth of established melanoma.  As shown in 
Fig 4.2A, tumour progression was dramatically retarded by daily i.p. injection of C3aRA 
(commencing day 7), with tumour area remaining relatively constant from this time, and 
significantly smaller than in the vehicle-treated control group; excised tumour weights at day 
14 were also significantly smaller in the C3aRA treatment group (Fig 4.2B, C).  Similarly, 
survival rates were significantly improved by treatment with C3aRA (Fig 4.2D). Together 
these data suggest C3aR as a potential therapeutic target for the treatment of established 
melanomas.   
Figure 4.2. C3aR blockade inhibits the growth of established primary melanoma. 
Tumour areas (A) and weight (B) of excised tumours from C57Bl/6J mice treated from 
day 7 with either saline (vehicle, ●) or selective C3aR antagonist (C3aRA; SB290157, 
1mg/kg/day, ). Data expressed as mean ± SD from 3 independent experiments (n=9-
10/group).  Photographs (C) show representative tumours from mice treated with vehicle 
alone or C3aR antagonist. Kaplan-Meier curve (D) shows increased survival of mice 
treated with C3aRA compared with vehicle alone; the terminal event is euthanasia once 
tumours reach maximal size; (n=7/group). **p<0.01, ****p<0.0001, Permutation test 




4.3.4 Melanoma cells express functional C3aR 
4.3.4.1 Immunofluorescence staining   
In light of our results showing C5aR expression by murine melanoma cells (Chapter 3), along 
with the recent demonstration that tumour-derived complement proteins can promote ovarian 
tumour growth via autocrine mechanisms (Cho et al., 2014), we determined whether 
melanoma cells also express C3aR. This was confirmed by immunostaining (Fig 4.3A) and 
FACS analysis which showed C3aR expression by cultured B16 cells (Fig 4.3C), albeit at 
lower levels than for J774 macrophages which are known to have high levels of C3aR 
expression.  Human melanoma cell lines also expressed low levels of C3aR (Fig 4.3B, D).  
4.3.4.2 Signal activation 
Although stimulation of B16 cells with recombinant human C3a or a selective C3aR agonist 
failed to initiate a calcium mobilization response (not shown), ERK and AKT signalling 
pathways were activated (Fig 4.3E), suggesting that the receptors are functionally coupled. 
Stimulation of cells with a C3aR agonist had no significant effect on tumour cell proliferation 
(data not shown), but cell migration was significantly increased (Fig 4.3F), suggesting that 





Figure 4.3.  B16 melanoma cells express functional C3aR.  Photomicrographs show 
immunostaining of (A) cultured B16 melanoma cells and J774 macrophages with Alexa-
647-conjugated anti-mouse C3aR (orange), and (B) human melanoma cell lines with anti-
human C3aR (green); nuclei are counterstained with Hoechst 33342 (blue); scale bar = 
25µm. Representative FACS profiles for (C) cultured B16 melanoma (blue line) and J774 
(orange line) cells stained with anti-C3aR or isotype control (red line) and (D) human 
melanoma cell lines..Representative immunoblots (E) show levels of phosphorylated 
ERK1/2 or phosphorylated AKT following stimulation of B16 cells with recombinant 
human C3a (hC3a; 10-8 mol/L) for 0-60 mins. Immunoblotting for total ERK or AKT was 
used as loading control.  Densitometry of bands shows ERK or AKT activation relative to 
the untreated control (0 mins). Histogram (F) shows B16 cell migration following 
treatment with DMEM alone or containing C3a agonist (C3a-A; 
WWGKKYRASKLGLAR, 10-6 mol/L) or 5% FCS for 24 hours.  Data expressed as mean 




4.3.5 Tumour-infiltrating leukocyte populations are altered in C3aR deficient mice 
4.3.5.1 Immunofluorescence staining of tumour tissue 
Despite our demonstration that B16 melanoma cells are able to respond to C3a, our in vivo 
experiments showed that the growth of C3aR-expressing B16 melanoma cells was markedly 
inhibited in C3aR-deficient mice (Fig 4.1), indicating a predominant role for host-expressed 
C3aR in the anti-tumour response.  To further investigate the effects of host-expressed C3aR 
on tumour growth, we compared tumour infiltrating leukocyte populations in C3aR-/- and 
WT mice. Immunofluorescence staining of tumour tissue demonstrated a band of (CD45+) 
leukocytes encapsulating subcutaneous B16 tumours (Fig 4.4A, B), with cells also infiltrating 
tumour tissue in both C3aR-/- and WT mice (Fig 4.4C, D).  Many tumour infiltrating 
leukocytes stained positive for neutrophils (Ly6G+; Fig 4.4E, F), with neutrophil numbers 
apparently increased in C3aR-deficient mice.  Macrophages (F4/80+; Fig 4.4G, H) and T 
lymphocytes (CD3+; Fig 4.4I, J) were also evident. 
4.3.5.2 Flow cytometric analysis of tumour tissue from C3aR-deficient mice  
To quantitate potential alterations in the immune response to B16 melanomas, we analysed 
tumour infiltrating leukocyte populations by flow cytometric analysis (Fig 4.5A).  Although 
the proportion of total leukocytes (CD45+) within tumour tissue was not significantly altered 
in C3aR knockout mice (5.8 ± 2.7 % versus 4.7 ± 2.9 % in WT), the contribution of 
 
  
Figure 4.4.  Leukocyte infiltration of B16 melanomas from C3aR-deficient and wild-
type mice.  Immunostaining of B16 tumours from WT and C3aR -/- mice shows CD45+ 
cells (green) encapsulating the tumour tissue (A, B; dotted line indicates leukocyte 
‘capsule’), and within tumour tissue (C, D). Many tumour infiltrating cells are neutrophils 
(Ly6G+; green; E, F), but macrophages (F4/80+; red; G, H), and T lymphocytes (CD3+; 
green; I, J), are also present. Tissue stained with an isotype control antibody (K). Nuclei 





CD11b+Ly6G+ cells (neutrophils) was significantly higher (16.6 ± 8.1 % of total leukocytes 
versus 9.7 ± 4.8 % in WT), a result that is in accord with a prior report that C3aR deficiency 
causes the egress of neutrophils from bone marrow (Wu et al., 2013).  However, although 
previous studies have demonstrated differences in the activation status (Fridlender et al, 
2009; Piccard et al, 2012) of tumour-associated neutrophils, we found no significant 
difference in neutrophil expression of activation markers CD62L or CXCR4 (not shown).  
The relative contributions of monocytes (CD11b+Ly6C+) and total T lymphocytes (CD3+) 
were also significantly higher, but the proportion of macrophages (F4/80+) (Fig 4.5A) B 
lymphocytes (data not shown) were unaltered.  In contrast to previous demonstrations that 
C5a promotes tumour growth via recruitment of myeloid-derived suppressor cells (MDSC) 
(Corrales et al., 2012; Gunn et al., 2012; Markiewski et al., 2008a), the percentages of tumour 
infiltrating CD11b+GR1+ cells) were not significantly different in C3aR-/- compared with 
WT mice.  However, since the GR1 antibody used to identify MDSC recognises a common 
epitope of Ly6G and Ly6C (Fleming et al., 1993), it is not possible to discriminate between 
neutrophils and granulocytic MDSC.  Investigation of tumour infiltrating CD3+ T lymphocyte 
subsets showed an increase in the proportion of CD4+ T lymphocytes, but the proportion of 
CD8+ T lymphocytes was not significantly different between WT and C3aR-/- mice; 
CD4/CD8 ratios were 2.99 and 2.64 respectively. While the proportion of regulatory T cells 
(CD4+CD25+Foxp+; Tregs) was unchanged, Th1 (CD4+IFNγ+), Th2 (CD4+IL4+) and Th17 
(CD4+IL17A+) subsets were all significantly higher in tumours from C3aR-/- mice (Fig 
4.5A).   
To investigate the distribution of these immune cell populations, we next analysed leukocyte 
sub-populations in bone marrow, blood, draining lymph nodes and spleen from tumour-
bearing wild-type and knockout mice.  Flow cytometric analysis of bone marrow cells (Fig 
4.5B) revealed a reduction in monocytes, but no significant difference in the proportion of  
neutrophils in C3aR-/- mice.  Analysis of blood from C3aR-/- and WT mice showed no 
difference in monocytes or T lymphocyte populations but the percentage of neutrophils was 
reduced (Fig 4.5C), possibly reflecting the increased sequestration of neutrophils to the 
tumour site.  Although no significant differences were detected in neutrophils, monocytes or 
total T cell populations, the percentages of Th1, Th2 and Th17 cells were increased in 
draining lymph nodes of C3aR-/- mice (Fig 4.5D). Within the spleen, the proportions of 




CD11b+Ly6G+ (neutrophils) were not altered.  Total T lymphocytes were also significantly 
higher, as was the proportion of CD4+ cells, with Tregs, Th1 and Th17 CD4+ subsets all 
increased (Fig 4.5E). Analysis of leukocyte populations in healthy mice showed that the 
proportion of bone marrow (CD11b+Ly6G+) neutrophils was slightly lower in C3aR-deficient 
compared with their wild-type counterparts (Fig 4.6A), although this was not significant.  
However there was a significantly higher percentage of circulating (CD11b+Ly6G+) 
neutrophils (Fig 4.6B).  Other leukocyte populations were similar in blood and bone marrow 





Figure 4.5. Tumour-infiltrating leukocyte populations are altered in C3aR deficient 
mice.  Percentages of leukocyte sub-populations in tumour tissue (A), bone marrow (B), 
blood (C), draining lymph nodes (DLN; D) and spleen (E) from WT and C3aR-/- mice: 
total leukocytes (CD45+), monocytes (CD11b+Ly6C+), neutrophils (CD11b+Ly6G+), 
MDSCs (CD11b+GR1+), macrophages (F4/80+), total (CD3+), CD4+ and CD8+ T 
lymphocytes;.  CD4+ T lymphocyte subsets, Treg (CD4+CD25+FoxP3+), Th1 
(CD4+IFNγ+), Th2 (CD4+IL4+) and Th17 (CD4+IL17+). Data expressed as % positive 
cells (mean ± SD); results representative of 2 independent experiments (n=7-8/group). 




4.3.6. C3aR antagonism alters tumour infiltrating leukocyte populations  
FACS analysis of tumour infiltrating leukocyte populations in mice treated with SB290157 
(C3aRA; Fig 4.7A), showed a similar trend to C3aR-/- animals, with the percentage of 
tumour infiltrating neutrophils (CD11b+Ly6G+) increased by drug treatment. However, as for 
C3aR-/- mice, the proportion of CD11b+GR1+ cells was not significantly altered in C3aRA-
treated mice, but tumour-associated macrophages were reduced.  As observed in C3aR-/- 
mice, the percentages of total and CD4+ T lymphocytes were higher in tumours following 
drug treatment; proportions of Th1, Th2 and Th17 subsets were also increased. Bone marrow 
(Fig 4.7B) showed greater effects on myeloid cell populations than were observed in C3aR 
knockout mice, with C3aR antagonism causing significant reductions in all myeloid cell 
populations (identified by Ly6C, Ly6G and GR1 expression). Whereas blood neutrophils 
were reduced in knockout mice, they were increased in antagonist-treated mice.  The 
proportion of CD11b+GR1+ cells remained unchanged, but macrophages, CD8+ and Treg 
cells reduced significantly (Fig 4.7C).  
Figure 4.6. Leukocyte populations in healthy C3aR deficient and wild-type mice.  
Percentages of leukocyte sub-populations in bone marrow (A) and blood (B) from WT 
and C3aR-/- mice: total leukocytes (CD45+), monocytes (CD11b+Ly6C+), neutrophils 
(CD11b+Ly6G+), MDSCs (CD11b+GR1+), macrophages (F4/80+), total (CD3+), CD4+ and 
CD8+ T lymphocytes. Data expressed as % positive cells (mean±SD); representative of 2 









Figure 4.7. C3aR antagonism alters tumour infiltrating leukocyte populations.  
Percentages of leukocyte sub-populations in tumour tissue (A), bone marrow (B), blood 
(C) and spleen (D) from WT mice treated with SB209157 (1mg/kg/day) or vehicle 
commencing once tumours became palpable: total leukocytes (CD45+), monocytes 
(CD11b+Ly6C+), neutrophils (CD11b+Ly6G+), MDSCs (CD11b+GR1+), macrophages 
(F4/80+), total (CD3+), CD4+ and CD8+ T lymphocytes; results of 2 independent 
experiments, n=16-17/group.  CD4+ T lymphocyte subsets, Treg (CD4+CD25+FoxP3+), 
Th1 (CD4+IFNγ+), Th2 (CD4+IL4+) and Th17 CD4+ (CD4+IL17+). Data expressed as % 
positive cells (mean ± SD; n=9-10/group); *p< 0.05, **p<0.01, ***p<0.001, 




Although macrophages were unaltered in draining lymph nodes from C3aRA-treated mice 
(Fig 4.7D), total T lymphocytes, T lymphocyte subsets (CD4+ and CD8+) and Th2 cells were 
all significantly increased. Although the proportions of CD11b+Ly6C+ (monocytes), 
CD11b+Ly6G+ (neutrophils) and F4/80+ (macrophages) were not significantly altered in 
spleens from C3aRA-treated mice, CD11b+GR1+ cells were significantly lower.  Whereas 
CD8+ T cells were significantly lower, total (CD3+) and CD4+ T lymphocytes were 
significantly higher in the drug-treated group, coincident with significant increases in Treg 
and Th2 cells (Fig 4.7E).   
4.3.6 Neutrophil depletion rescues the tumour inhibitory effect of C3aR deficiency  
Given the FACS data showing a clear increase in tumour-infiltrating neutrophils in C3aR-
deficient and antagonist-treated mice, we proposed that the influx of neutrophils into the 
tumour could be one reason for the reduction in tumour growth. To determine whether 
neutrophils actively contribute to the tumour inhibition observed in the absence of C3aR 
signalling, we used a monoclonal antibody (α-Ly6G; 1A8) to deplete these cells (Daley et al., 
2008).  The efficacy of neutrophil depletion from WT and C3aR-/- mice was confirmed by 
FACS analysis of blood (Fig 4.8A).  Neutrophil depletion slowed tumour growth in WT 
mice, although excised tumour weight was not significantly reduced (Fig 4.8B, C).  
Conversely, the lack of neutrophils reduced the tumour inhibitory effects observed in C3aR-/- 
mice, such that excised tumour weight was not significantly different from that of WT mice 
treated with the isotype control antibody (I.C., 2A3; Fig 4.8C). FACS analysis (Fig 4.8D) 
also demonstrated that neutrophil depletion was associated with a significant reduction in 
tumour-infiltrating CD4+ T lymphocytes in C3aR-/- mice, with levels not significantly 
different to those in isotype control-treated mice, thus suggesting that neutrophils may be 
regulating the secondary T cell response to tumour.  Interestingly, anti-Ly6G treatment also 
removed the majority of CD11b+GR1+ cells in both wild-type and knockout mice, indicating 





4.3.7 Neutrophils are associated with human melanoma 
Given our finding of a neutrophilic response in mouse melanoma models, we next determined 
whether neutrophils may also be associated with human melanoma tissue. Staining of 
melanoma tissue arrays for neutrophil esterase showed neutrophils in some biopsies, thus 
suggesting the potential to use C3aR-modulating drugs to manipulate neutrophil populations 
in human melanoma. 
Figure 4.8. The tumour inhibitory effect of C3aR deficiency is rescued by neutrophil 
depletion. FACS results (A) verify neutrophil depletion in blood. Tumour area (B) and 
excised tumour weights (C) for WT and C3aR-/- mice treated with neutrophil depleting 
anti-Ly6G (1A8) or isotype control (2A3). Tumour infiltrating leukocyte populations (D) 
for WT and C3aR-/- mice treated with neutrophil depleting anti-Ly6G (1A8) or isotype 
control (2A3). Panel (E) shows neutrophils in human melanoma tissue.  Data expressed as 
mean ± SD; results representative of 2 independent experiments (n=6/group); * p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, Permutation test (B), Kruskal Wallis test followed 
by Dunn’s multiple comparisons test (A, C, D).  
           
           
              
             
             
                




4.3.8 Influence of C3aR deficiency on cytokine/chemokine expression 
To determine how C3a regulates the inflammatory milieu within tumour microenvironment, 
we analysed plasma and tumour tissue extracts for a panel of cytokines and chemokines 
previously implicated as regulators of the anti-tumour response.  As shown in Fig 4.9, plasma 
G-CSF was significantly reduced in C3aR-/- mice whereas IL-1β was increased.  There were 
no significant differences in plasma chemokine levels in C3aR-/- compared with WT mice 
(Fig 4.10).  Although most chemokines were slightly increased, only CCL5 (RANTES) 
showed significant up-regulation in tumour tissue extracts from C3aR-/- mice.. 
Figure 4.9.  Influence of C3aR deficiency on cytokine expression.  Cytokine levels in 
plasma and tumour tissue from WT (●) and C3aR-/- () mice (n=6-8/group).  Data 
expressed as pg/ml (for plasma) or pg/mg (for tumour tissue), mean ± SD (n=7-8/group); 







Figure 4.10.  C3aR deficiency influences chemokine expression.  Chemokine levels in 
plasma and tumour tissue from WT (●) and C3aR-/- () mice (n=6-8/group).  Data 
expressed as pg/ml (for plasma) or pg/mg (for tumour tissue), mean ± SD (n=7-8/group); 





4.3.9 C3aR signalling contributes to the growth of other tumour types 
Finally, to determine whether or not the tumour promoting effects of C3aR signalling are 
restricted to the B16 melanoma model, we investigated the growth in C3aR-/- mice of two 
other tumour models: the murine melanoma cell line SM1WT1 which bears the BRAFV600E 
mutation harboured by approximately 50% of human melanomas (Knight et al., 2013) and 
the colon cancer cell line MC38.  Similar to our results with B16 melanoma, the growth of 
both tumour types was significantly slowed in C3aR-/- mice compared with WT mice (Fig 
4.11A, C).  Analysis of excised tumour weights at termination confirmed that tumours were 
smaller in C3aR-/- mice (91% reduction for SM1WT1 and 58% for MC38 tumours; Fig 
4.11B, D), thus suggesting the potential of C3aR as a therapeutic target for a range of tumour 
types.  
  
Figure 4.11 C3aR signalling contributes to tumour growth in other tumour models. 
Tumour areas (A, C) and excised weights (B, C) for SM1WT1 melanoma (A, B) and 
MC38 colon carcinoma (C, D) grown in WT (●) and C3aR-/- () mice.  Data expressed as 
mean ± SD (n=6-10/group); ** p<0.01 ***p<0.005, ****p<0.0001, Permutation test (A, 






The complement system, in particular the canonical pro-inflammatory anaphylatoxin C5a, is 
now widely implicated for a role in tumour growth, with both tumour-promoting and tumour-
inhibitory effects reported, depending on tumour type, immune status of the host and C5a 
levels (Corrales et al., 2012; Gunn et al., 2012; Kim et al., 2005; Markiewski et al., 2008a; 
Nunez-Cruz et al., 2012).  In contrast to C5a, the involvement of the upstream complement 
activation fragment C3a in tumourigenesis has not been extensively investigated.  The 
present study used both C3aR-deficient mice and C3aR therapeutic inhibition, to identify a 
hitherto unknown role for C3a-C3aR in regulating tumour growth in murine models of 
melanoma.  The demonstration of similar anti-tumour effects in a murine model of colon 
carcinoma suggests the wider potential of C3aR as a therapeutic target for a range of cancers.  
We demonstrated that C3aR is expressed at low levels by B16 melanoma cells in vitro and in 
vivo, and that these cells are able to respond directly to C3a, activating ERK and AKT 
signalling pathways and resulting in enhanced migratory capacity.  These results are in 
accord with those of Cho et al (2014) who recently demonstrated the expression of C3aR by 
murine ovarian cancer cell lines.  However, unlike Cho and co-workers, the present study 
failed to show any effect on cell proliferation. These findings, along with the deposition of 
complement activation products in human melanoma (Chapter 3), and other tumours (Ajona 
et al., 2013; Gorter and Meri, 1999; Niculescu et al., 1992), suggests that activation of 
tumour-expressed C3a receptors in vivo is possible.  However the tumour microenvironment 
also includes inflammatory infiltrates (Gregory and Houghton, 2011) and since inflammatory 
cells, in particular myeloid cells, are known to express high levels of C3aR (Klos et al., 
2009), the anti-tumour effects may instead be indirect, via effects on tumour infiltrating cells.  
Indeed, our demonstration that growth of C3aR-expressing B16 cells is retarded in C3aR-
deficient mice supports the premise that the tumour-promoting effects of C3a-C3aR 
signalling are mediated via the host immune system.   
We also demonstrated the potent arrest of B16 tumour growth in vivo via C3aR antagonism 
of established tumours. It should be noted that the C3aRA used in this study (SB290157) has 
been demonstrated to have C3aR agonistic and off-target activity (Woodruff, 2015). However 
our findings of reduced tumour growth using SB290157 are in accord with our findings in 




model, although we cannot rule out other potential off-target effects of SB290157.  Our 
findings are also in line with those of Markiewski et al (2008) who reported reduced tumour 
growth in C3-deficient mice, and similarly interpreted the results as being due to changes in 
the anti-tumour immune response.  C3 cleavage produces C3a as well as generating 
downstream C5a, and the demonstration that tumour growth was reduced in C5aR1 
antagonist-treated or C5aR1-deficient mice led these researchers to attribute the tumour-
promoting effects solely to C5a.  However the present study demonstrates that C3a also 
impairs an effective anti-tumour response.  We further show that the anti-tumour effect 
observed in C3aR-/- mice is not augmented by treatment with the C5aR1 antagonist PMX53, 
implying that in this model the tumour promoting effects of C3a are at least as potent as those 
of C5a.  Importantly, our results highlight the fact that these two receptors have discrete 
functions, affecting different aspects of the immune response.  
Evidence that C3a mediates its effects on tumour growth via the immune system is provided 
by FACS analysis showing alterations in tumour infiltrating leukocyte populations in the 
absence of C3aR signalling.  In contrast to C5aR1 which has been demonstrated to act via 
induction of MDSC and Tregs and inhibition of T lymphocyte responses (Chapter 3), we 
show that C3aR inhibition leads to an increase in tumour infiltrating 
neutrophilic/granulocytic populations, monocytes and CD4+ T-cells.  The enhanced 
neutrophil contribution to tumour inflammatory infiltrates of C3aR-/- and C3aRA-treated 
mice is in accord with the recently identified role for C3a-C3aR signalling in the retention of 
neutrophils in the bone-marrow, with C3aR deficiency causing the selective egress of 
neutrophils in response to ischemic injury or G-CSF administration (Galdiero et al., 2013;Wu 
et al, 2013). Although Wu and co-workers found that C3aR-deficiency did not affect resting 
immune cell populations, the present study showed an increase in circulating neutrophils in 
healthy C3aR-deficient mice. Interestingly cytokine analysis showed a reduction in plasma 
G-CSF levels in tumour bearing C3aR-/- mice, a result in line with previous studies showing 
that G-CSF levels are inversely correlated with neutrophil counts, and likely due to negative 
feedback mechanisms at the transcriptional level (Bugl et al., 2013).  In contrast to C5aR1-
deficient mice which showed reduced levels of key chemokines including CCL2, CCL3, 
CCL5 (Chapter 3) in tumour tissue, C3aR-deficient mice tended to have higher chemokine 




Our demonstration that neutrophil depletion significantly reverses the tumour inhibitory 
effects observed in C3aR deficient mice implicates neutrophils as major contributors to the 
anti-tumour effects of C3aR deficiency/antagonism. Neutrophils are generally thought to 
promote tumour cell proliferation, angiogenesis and metastasis via the production of 
chemokines, cytokines and reactive oxygen species; they also contribute to MDSC 
populations which inhibit T cell responses (Gregory and Houghton, 2011). Unfortunately 
there are currently no antibodies available that can effectively discriminate between different 
neutrophil populations, including granulocytic MDSC. Indeed the demonstration that the 
majority of tumour infiltrating MDSC are removed by treatment with the anti-Ly6G antibody 
indicates that in this model, the majority of MDSC are granulocytic. However, there is 
evidence that under certain conditions neutrophils can exert efficient anti-tumour activity 
(Souto et al., 2011), and activation of neutrophils by primary tumours has been shown to 
inhibit metastatic seeding (Granot et al., 2011).  These differing roles of neutrophils in 
tumour growth may be explained by differences in activation status.  Fridlender et al (2009) 
demonstrated in lung cancer models that like macrophages, neutrophils have differential 
states of activation: a pro-tumourigenic phenotype identified by increased expression of 
chemokines and growth factors (eg CCL2, CCL5, VEGF-A), and an anti-tumour phenotype 
associated with increased expression of pro-inflammatory cytokines (eg TNF-α), chemokines 
(CCL3) and adhesion molecules (ICAM-1).  They showed that the presence of TGFβ within 
the tumour environment induces a population of pro-tumourigenic neutrophils, whereas 
TGFβ blockade resulted in recruitment and activation of anti-tumour neutrophils.  More 
recently this same group has shown that tumour associated neutrophils have a unique 
transcriptional profile compared to naïve bone marrow neutrophils, and also differ from 
granulocytic MDSC (Fridlender et al., 2012).  Thus the effects of neutrophils on tumour 
growth may depend on their activation status, such that a shift in cytokine expression within 
the tumour microenvironment from acute to chronic inflammation converts anti-tumour 
effector cells to tumour promoting neutrophils (Souto et al., 2011).  This is supported by 
recent studies showing that neutrophils at the early stages of tumour development are more 
cytotoxic towards tumour cells (Mishalian et al., 2013) and capable of stimulating effective T 
cell responses (Eruslanov et al., 2014), but at later stages develop a pro-tumour phenotype.  
Thus we propose that C3aR inhibition augments the sequestration of naïve neutrophils into 




neutrophil response.  This may include the recruitment and activation of other anti-tumour 
effector cells, including T lymphocytes, via neutrophil release of cytokines and chemokines 
that augment an effector T cell response.  Indeed our demonstration that CD4+ T lymphocyte 
populations are increased in the absence of C3aR signalling, but return to normal (wild-type) 
levels following neutrophil depletion suggests that these newly mobilised neutrophils may 
promote effective anti-tumour T cell responses.  This hypothesis is in accord with previous 
reports, for example by Medina-Echeverz et al (2011)  who showed that an efficient anti-
tumour response can be generated by altering the myeloid cell population within the tumour 
microenvironment and facilitating effector T cell infiltration.  Our demonstration that 
neutrophils are present in human melanoma tissue suggests the potential to use C3aR-
targeting drugs to manipulate neutrophil populations within the tumour, and thus tip the 
balance towards an anti-tumour response.   
Although we were unable to demonstrate significant differences in expression of neutrophil 
activation markers CD62L and CXCR4 (data not shown), the up-regulation of IL-1β and 
CCL5 in plasma and tumour tissue (respectively) from C3aR-/- mice is in accord with the 
reported up-regulation of M1-associated cytokines/chemokines in anti-tumour myeloid cell 
populations (Medina-Echeverz et al., 2011).  As discussed above, CCL5 has been associated 
with pro-tumourigenic neutrophils, and increased CCL5 levels have been associated with 
unfavourable outcomes in some cancers (Niwa et al., 2001), it is a predictor of survival in 
others (Chew et al., 2012; Moran et al., 2002).  CCL5 has been implicated for a role in 
regulating anti-tumour immunity (Johrer et al., 2008; Mule et al., 1996), and shown in a 
mouse melanoma model to synergize with CXCR3 ligands to attract effector T cells into 
cutaneous metastases and inhibit tumour growth (Hong et al., 2011).  FACS analysis of 
tumour infiltrating T lymphocyte populations showed C3aR-deficiency/inhibition increased 
Th1, Th2 and Th17 populations, but had no effect on CD8+ T lymphocytes or Tregs.  
Although effective anti-tumour responses have been traditionally attributed to CD8+ CTL 
supported by Th1 cells (Fridman et al., 2012; Ye et al., 2013), this is not always the case.  
Depending on the tumour type, anti-tumour responses can occur independently of cytotoxic 
CD8+ T cells, mediated directly by Th1 Th2 or Th17 cells (Chu et al., 2006; Corthay et al., 
2005; Kim and Cantor, 2014).  Th2 cells have been reported to amplify the innate immune 
response to tumours by directly recruiting tumouricidal myeloid cells into the tumour 




play a critical role in immunity to B16 melanoma (Mattes et al., 2003; Zhang et al., 2009).  
Th17 populations may also be associated with favourable outcomes, for example, in 
melanoma (Martin-Orozco et al., 2009a; Muranski et al., 2008) and oesophageal (Lv et al., 
2011) cancers.   
Th17 cells comprise approximately 0.1-0.5% of circulating CD4+ T cells in humans, but 
significantly higher densities are observed within tumour tissues, including melanoma (Su et 
al., 2010), prostate, fibrosarcoma, head and neck cancers (Kryczek et al., 2007). However 
their role in tumour growth is controversial, with tumour infiltrating Th17 cells reported to 
either contribute to an anti-tumour cytotoxic T cell response or promote tumour growth by 
facilitating angiogenesis and suppressing the anti-tumour response (Hemdan, 2013). In 
animal models, induction of Th17 cells has been shown to support anti-tumour immunity.  
For example, up-regulated expression of IL-6 in a pancreatic tumour model was shown to 
skew the balance towards Th17 cells, delaying tumour growth and improving survival 
(Gnerlich et al., 2010) while antigen-specific Th17-polarised cells eradicated established B16 
melanoma (Muranski et al., 2008) and metastatic prostate tumours (Kottke et al., 2007). 
Muranski and co-workers showed that the therapeutic effect of Th17 cells is dependent on 
their production of IFNγ.  Our demonstration of increased tumour infiltrating Th17 cells in 
the absence of C3aR signalling is in accord with a previous study by Lim et al (2012) who 
showed in a mouse model of allergic lung inflammation that C3aR deficient mice had higher 
frequencies of both neutrophils and Th17 cells in the lung. There is also evidence for direct 
cross-talk between activated neutrophils and Th17 cells, with both cell types producing a 
range of chemokines and cytokines capable of recruiting the other.  Neutrophils mediate the 
Th17 pathway (Cua and Tato, 2010), via production of IL17 (Li et al., 2010) and 
chemoattractants such as CCL2, while cytokines produced by Th17 cells (including IFNγ, 
TNF-α, GM-CSF) favour recruitment, activation and prolonged survival of neutrophils at 
inflammatory sites (Pelletier et al., 2010).  Although the present study found no significant 
changes in CCL2, IL17 or IFNγ, Th17 cells can also be recruited by CCL5 (Su et al., 2010). 
Clearly however, the impact of these changes in T cell populations on the anti-tumour 
response  remains to be determined, for example by antibody depletion studies. In summary, 
this study identifies an important role for C3a/C3aR signalling in promoting the growth of 
melanoma and colon cancer, and provides evidence that these pro-tumour effects are 




tumour promoting effects, our data suggest that they act via different mechanisms.  The 
results show that C3aR deficiency or therapeutic antagonism leads to increased tumour 
infiltrating leukocyte populations, including neutrophils and CD4+ T lymphocytes.  Although 
neutrophils are generally thought to promote tumour growth, there is considerable evidence 
in the literature that neutrophils can be manipulated to exert efficient anti-tumour activity.  
We propose that by enhancing neutrophil infiltration populations, C3aR inhibition may 
change the inflammatory equilibrium within the tumour environment and tip the balance from 
a suppressive environment containing a majority of tumour-promoting granulocytic MDSC 
towards a more effective anti-tumour response. This hypothesis is supported by the 
demonstration that tumour infiltrating T lymphocytes, specifically CD4+ populations, are also 
increased.  The association of C3aR-deficiency with increased tumour infiltrating CD4+ cells 
suggests that a positive feedback loop may develop whereby the secretion of chemokines and 
cytokines by neutrophils sequestered to the tumour microenvironment promotes CD4+ 
recruitment and expansion; cytokines produced by CD4+ cells may in turn favour neutrophil 
recruitment and survival.  Further studies are required to determine the precise mechanisms 
by which C3a influences the immune response to melanoma, in particular how C3a 
deficiency/inhibition influences neutrophil phenotype and function, whether the mechanisms 
are similar in other tumour types, and the relationship between the effects C3aR and C5aR.  
The stage of tumour development and commencement of treatment may also be important, 
and thus future studies should compare the effects of treating advanced and metastatic 
tumours.  Nevertheless the results suggest the potential of C3aR as a therapeutic target for 























5.1 GENERAL DISCUSSION 
Melanoma is the most deadly form of skin cancer, with 232,000 new cases and 55,000 deaths 
globally in 2012 (World Health Organisation Report, 2014). The incidence of melanoma is 
increasing world-wide, and Australia has the highest rate of melanoma in the world, with 
over 12,500 new cases diagnosed each year. Despite recent advances in treatment of 
disseminated melanoma including inhibitors of BRAF or MEK (for patients with BRAF 
mutations) or immunotherapy (anti-CTLA-4 and anti-PD-1 antibodies) (Finn et al., 2012), 
metastatic melanoma remains an incurable disease with a 3-year survival rate of approx. 
15%, and median survival of only 6-9 months (Eggermont et al., 2014). Hence there is an 
urgent need for new therapies for advanced melanoma. Thus this thesis aimed to investigate 
one possible approach to the problem – targeting the complement anaphylatoxins C3a and 
C5a.   
The complement system is a key component of the innate immune system, and a major 
consequence of complement activation is the production of anaphylatoxins C3a and C5a 
(Dutow et al., 2014; Markiewski and Lambris, 2007; Mukherji et al., 1986). Cancer cells are 
thought to evade complement-mediated destruction by up-regulating endogenous 
complement inhibitors (Fishelson et al., 2003; Sato et al., 2010), and complement activation 
products have been detected in human tumour tissue (Corrales et al., 2012; Lucas et al., 1996; 
Niculescu et al., 1992). Although the complement system has long been thought to contribute 
to antibody-dependent responses to tumours (Gelderman et al., 2004), its contribution to 
other aspects of the anti-tumour response has only recently begun to be investigated. The 
majority of investigations into the role of complement anaphylatoxins in tumour growth have 
been confined to complement C5a, with C5a-C5aR1 signalling demonstrated to contribute to 
tumour growth in cervical, lung, lymphoma and ovarian cancer models (Corrales et al., 2012; 
Markiewski et al., 2008a; Markiewski et al., 2008b; Nunez-Cruz et al., 2012). Despite 
evidence that serum C3a levels are up-regulated in many cancer patients (Maher et al., 2011) 
and that C3aR is expressed by some tumour cells (Cho et al., 2014; Xu et al., 2008) there is 
currently no information regarding the role of C3a-C3aR signalling in tumourigenesis. 
Collectively, these gaps in knowledge prompted us to explore and elucidate the contribution 
of complement anaphylatoxins C3a and C5a to melanoma development and growth. Hence 




receptors C3aR, C5aR1 and C5aR2 are therapeutic targets for melanoma. The effects of 
C3aR and C5aR1/2 deficiency or antagonism were investigated in murine models of 
melanoma. 
In agreement with previous reports of complement activation in human tumour tissue (Ajona 
et al., 2013; Niculescu et al., 1992), the complement activation product C4d was detected in 
human melanoma tissue, thus demonstrating that the complement system is activated, and 
may play a role in melanoma progression. Murine B16 melanoma cells were shown to 
express the complement anaphylatoxin receptors, C3aR, C5aR1 and C5aR2; C3aR was also 
detected on human melanoma cell lines, albeit at low levels. Further, C3aR and C5aR1 
expressed by B16 cells were capable of signal activation via ERK1/2 and AKT pathways, a 
result that is in accord with the recent study demonstrating C3aR and C5aR1 expression by 
murine ovarian cancer cell lines (Cho et al., 2014). In contrast to that study however, the 
present study found no significant effect of C5a on proliferation or migration of B16 cells, 
although C3a increased cell proliferation.  
In accord with previous studies in other tumour models (Corrales et al., 2012; Markiewski et 
al., 2008a; Nunez-Cruz et al., 2012), this thesis demonstrates a deleterious role for C5aR1 
signalling in melanoma growth (Chapter 3). It also demonstrates for the first time, a role for 
the alternate C5a receptor, C5aR2, in modulating the effects of C5aR1 signalling on tumour 
growth. Importantly, it is the first to demonstrate a role for C3aR in promoting tumour 
growth, with C3aR deficiency protecting against B16 melanoma (Chapter 4). Importantly, the 
effects of C3aR inhibition were at least, if not more, potent as those of C5aR1 inhibition. 
Moreover, the demonstration that the growth of established tumours can be arrested by 
treatment with either C5aR or C3aR antagonists highlights the clinical therapeutic potential 
of C5aR/C3aR targeting drugs. C3aR deficiency was also protective in murine models of 
BRAFV600E mutant melanoma and colon cancer, suggesting the broader applicability of C3aR 
as a therapeutic target for cancer.  
The results suggest that the effects of both C3aR and C5aR1 are mediated primarily via the 
immune system, although the mechanisms are different: C5aR1 acts by promoting MDSC 
and Treg infiltration whereas C3aR acts by regulating neutrophil populations. Despite these 
different mechanisms, both C3aR and C5aR1 ultimately affect adaptive T cell responses. 




populations. Chapter 3 demonstrated that, as in other tumour types (Corrales et al., 2012; 
Markiewski et al., 2008a; Nunez-Cruz et al., 2012), the tumour microenvironment of C5aR1 
deficient mice contained fewer MDSC and Tregs. A potent chemoattractant for myeloid cells 
(Guo and Ward, 2005), C5a may act directly to attract MDSC into the tumour. However other 
chemokines were also down-regulated in these mice, including CCL2, CCL4 and CCL5, 
which are known to be responsible for regulating the infiltration of MDSC within tumour 
microenvironments (Boelte et al., 2011; Sevko and Umansky, 2013; Zollo et al., 2012). 
Among these, CCL2 has been shown to influence infiltration of MDSCs in melanoma and 
prostate cancer (Lesokhin et al., 2012; Zhang et al., 2010; Zollo et al., 2012), while high 
expression of CCL2 in human breast cancer is a strong indicator of early relapse (Sato et al., 
1995; Ueno et al., 2000; Valkovic et al., 2002). This reduction in CCL2 and CCL4 
expression, along with fewer macrophages in tumours from C5aR1-deficient mice, is in 
accord with Varney and co-workers (Varney et al., 2005) who demonstrated a correlation 
between macrophage infiltration and melanoma progression. Although not the focus of this 
thesis, the role of MDSCs and TAMs in promoting tumour growth via angiogenesis 
(Sawanobori et al., 2008; Varney et al., 2005) requires mention. By promoting infiltration of 
myeloid cell populations (including MDSC and TAMs), C5a and CCL2 may enhance 
angiogenesis (Boelte et al., 2011) and hence increase tumour growth.  
The changes in tumour infiltrating CD4+ T cell populations in C5aR-deficient mice (fewer 
Tregs and more Th2 cells) suggests that the tumour-promoting effects of C5a on melanoma 
growth may be partly due to Treg inhibition of CD4+ effector populations. Despite previous 
reports that C5aR signalling diminishes Treg function (Kwan et al., 2013; Strainic et al., 
2013), Gunn and co-workers (2012)have provided evidence that a high concentration of C5a 
inhibits Th1 and promotes Treg differentiation. One possibility is that the effect on Tregs is 
indirect, mediated via tumour infiltrating MDSC which have been shown to attract Tregs via 
CCR5 ligands, CCL4 and CCL5 (Schlecker et al., 2012). Interestingly healthy C5aR-
deficient mice in this study (without tumours) show inherent differences in circulating 
leukocyte populations: more neutrophils, fewer CD4+ and CD8+ T cell populations, but 
higher proportions of CD4+ subsets. However, in spite of fewer circulating T cells in C5aR-
deficient mice, the proportions of T cells within the tumour microenvironment of these mice 




Chapter 4 shows that C3aR deficiency/antagonism also results in alterations in tumour-
infiltrating leukocyte populations, albeit the nature of these changes are completely different. 
Specifically, the absence of C3aR leads to increased neutrophil and CD4+ T lymphocyte sub-
populations within the tumour microenvironment. Given the recent demonstration by Wu and 
co-workers (2013) that C3aR deficiency results in mobilisation of neutrophils from the bone 
marrow, we proposed that C3aR inhibition leads to increased infiltration of mature 
neutrophils into the tumour, and that this in turn tips the balance from a pro- to anti-tumour 
environment. The central role of neutrophils in the anti-tumour response was confirmed by 
neutrophil depletion experiments which significantly reversed the tumour inhibitory effects 
observed in C3aR-deficient mice; the percentage of tumour infiltrating CD4+ T lymphocyte 
also returned to control levels.  
The results presented here suggest the potential of neutrophils as anti-tumour effector cells. 
Although neutrophils are generally thought to promote tumour growth, by contributing to 
MDSC populations, angiogenesis and metastatic seeding (Gregory and Houghton, 2011), 
there is considerable evidence in the literature that neutrophils can be manipulated to exert 
efficient anti-tumour activity (Eruslanov et al., 2014).  Indeed it has been suggested that the 
effects of neutrophils on tumour growth may depend on their activation status, such that a 
shift in cytokine expression within the tumour microenvironment from acute to chronic 
inflammation converts anti-tumour effector cells to tumour-promoting neutrophils and 
MDSC (Fridlender et al., 2009; Murata and Baldwin, 2009; Souto et al., 2011).  Thus by 
promoting the sequestration of mature neutrophils, C3aR inhibition may change the 
inflammatory equilibrium within the tumour environment, and tip the balance towards an 
anti-tumour response. The concomitant increase in tumour infiltrating CD4+ cells suggests 
that a positive feedback loop may develop whereby chemokines and cytokines secreted by 
these newly recruited neutrophils act to promote CD4+ recruitment and expansion; cytokines 
produced by CD4+ cells may in turn favour neutrophil recruitment and survival. 
Unfortunately the inability of available antibodies to distinguish different neutrophil sub-
populations prevented us from confirming our hypothesis at this time. However the 
demonstrated presence of neutrophils in human melanoma tissue suggests the potential to use 
C3aR-targeting drugs to manipulate neutrophil populations within human tumours, to 
promote an effective anti-tumour response. In contrast to healthy C5aR-deficient mice which 




counterparts, healthy C3aR-deficient mice in our study showed minor differences, solely in 
circulating neutrophil levels.   
The increased contribution of neutrophils to the anti-tumour response in C3aR-deficient mice 
may also explain the different pattern of chemokine expression in these tumours. Whereas 
C5aR-deficiency was associated with significant reductions in key chemokines associated 
with chemoattraction of MDSC and Tregs, chemokine levels in tumour tissue from C3aR-
deficient mice tended to be higher than in their wild-type counterparts, although the 
differences reached statistical significance only for IL-1β and CCL5.  This increase in 
chemokine levels possibly reflects the increased contribution of neutrophils which are known 
to secrete a wide range of chemokines (Fleming et al., 1993). CCL5 has been associated with 
pro-tumourigenic neutrophils (Fridlender et al., 2009) and unfavourable outcomes in some 
cancers (Niwa et al., 2001).  However CCL5 has also been implicated for a role in regulating 
anti-tumour immunity (Johrer et al., 2008; Mule et al., 1996), and shown in a mouse 
melanoma model to synergize with CXCR3 ligands to attract effector T cells into cutaneous 
metastases and inhibit tumour growth (Coppola et al., 2011). In addition, the finding that the 
tumour inhibitory effects of C3aR deficiency were not augmented by C5aR inhibition 
suggests that the effects may actually be enhanced by the presence of C5a which may 
promote infiltration of newly mobilised neutrophils into the tumour.   
In contrast to the accepted paradigm that CD8+ T cells are the key mediators of effective anti-
tumour responses (Grabiner et al., 2014), the present study found that both C5aR1 and C3aR 
deficiency lead to changes in CD4+ T cell populations, in particular Th2 cells. Although Th2-
mediated immune responses are usually thought to promote tumour growth through 
promoting angiogenesis and mediating immunosuppression (Ellyard et al., 2007; Nishimura 
et al., 1999), they have been suggested to play an important role in the response to MHC class 
I negative tumours which are resistant to CD8+ cytotoxic T lymphocytes. Indeed the Th2 
response has been shown to be important for immunity against B16 melanoma (Fang et al., 
2009); (Mattes and Foster, 2003), and thus it is possible that the observed effects on T cell 
populations may be specific to the B16 melanoma model. 
In conclusion, this thesis highlights the importance of the complement anaphylatoxins in the 
immune response to tumour growth, and their potential as therapeutic targets for melanoma, 




growth, but identifies hitherto unknown roles for C5aR2 and C3aR.  Although C3a and C5a 
are often thought to have similar effects, this thesis suggests divergent functions.  However 
despite their different effects, both anaphylatoxins create an environment that favours tumour 
growth. The results presented in this thesis provide convincing evidence that therapeutic 
inhibition of C3aR and/or C5aR1 is an effective means to tip the balance towards an anti-
tumour response.  
5.2 FUTURE PROSPECTS 
The results presented in this thesis contribute to our understanding of the role of complement 
effector components C3a and C5a on tumour growth. However, further research is required to 
characterise these roles in melanoma and other tumours, the mechanisms by which C3a and 
C5a subvert the anti-tumour response and promote tumour growth, and how this knowledge 
can be applied clinically.  
The pro-tumour effects of C5a have been reported in murine models of cervical, lung, ovarian 
cancer, lymphoma and melanoma while this thesis is the first to demonstrate pro-tumour 
effects of C3aR in melanoma and colonic cancer. In particular, further studies are required to 
examine the effects of C3aR in other cancers. Additional research is also needed to determine 
the specific role of the complement components in the context of human disease and 
progression. The stage of tumour development and commencement of treatment may also be 
important, and thus future studies should compare the effects of treating advanced tumours.  
Little is known of the role of the complement anaphylatoxins in tumour metastasis, apart 
from two recent reports that C5a promotes the development of metastatic breast (Vadrevu et 
al., 2014) and colon cancer (Piao et al., 2015). Given that the majority of cancer deaths are 
due to metastatic disease, the role of C3aR and C5aR in tumour metastasis is an important 
question that requires urgent investigation.  
This thesis have provided convincing evidence that the effects of C3a and C5a on tumour 
growth are, at least in part indirect, likely via effects on host immune cells. However, given 
that complement receptors are expressed by tumour cell lines (Cho et al., 2014; Kim et al., 
2005) including human and mouse melanoma cells (Chapters 3 and 4), and that these 
receptors are capable of signal activation, direct effects on tumour cells are possible. To 
investigate this possibility, the growth of C3aR/C5aR-deficient tumours in wild-type mice 




As reported previously (Corrales et al., 2012; Gunn et al., 2012; Markiewski et al., 2008a), 
this thesis suggests that C5aR1 suppresses the anti-tumour response via induction of MDSC 
and Tregs (Chapter 3). Conversely, the results presented in Chapter 4 suggest that C3aR 
mediates its effects by regulation of neutrophil populations within the tumour 
microenvironment. While neutrophil depletion was shown to abrogate the anti-tumour effects 
in C3aR-deficient mice, further experiments are required to determine the precise 
mechanisms by which these C3aR-regulated neutrophils influence the anti-tumour response, 
and how they differ from other neutrophil populations.  Despite the absence of clear markers 
to distinguish the different neutrophil populations, further studies are required to characterise 
tumour infiltrating neutrophil populations in C3aR-deficient and wild-type mice, for example 
in regards to expression of chemokine receptors (including CXCR1, CXCR2, CXCR4) and 
other key genes known to be expressed by tumour associated neutrophils: Ccl2, Ccl3, Ccl5, 
Vegfa, Mmp9, Cxcr4, Tnf, Icam1 (Fridlender et  al, 2009; Mishalian et al, 2013). Experiments 
to determine the effects of depleting other leukocyte populations, in particular CD4 and CD8 
T cell populations, are also required, as well as further analysis of the influence of 
C3aR/C5aR deficiency on cytokine/chemokines within the tumour environment. Moreover, 
given the demonstration by Nunez-Cruz and co-workers (2012) that the primary role for C5a 
in ovarian cancer is to promote tumour neovascularisation, future studies should investigate 
the potential for C5a/C3a to promote tumour angiogenesis in melanoma. 
The present study found that combined C3aR/C5aR inhibition did not augment the anti-
tumour response, and suggested that the effects of C3a are as potent as those of C5a. 
However, further research is needed to establish the relationships between C3a and C5a 
signalling, and how both mediators can be modulated to achieve improved outcomes. A clear 
understanding of the precise mechanisms by which C3a and C5a regulate immune cell 
populations could provide an insight into how these complement components differentially 
regulate tumour immunity and thus lead to improved anti-tumour therapies. Finally, the 
potential for interactions with other therapeutic modalities (chemotherapy, radiotherapy and 
immunotherapy) needs to be investigated.  Indeed a recent report by Surace et al (2015) has 
shown that the local production of C3a and C5a is crucial to achieving an effective tumour 
response to radiotherapy.  This research highlights the complexity of the anti-tumour immune 
response and the need to fully understand the mechanisms involved before bringing new 




account these conflicting activities.  For example, the timing and dose of complement 
modulating drugs should be designed to maximise therapeutic benefits. 
Clearly, many questions remain to be answered before this research can be translated to the 
clinic.  There is also urgent need for improved C3aR-targeting drugs.  While PMX53 has 
proven to be safe for clinical application (Burns et al., 2013b; Kohl, 2006), the commercially 
available C3aR antagonist SB290157 is not suitable for administration to humans, and is 
reported to have agonist as well as off-target effects (Woodruff and Tenner, 2015). Although 
progress has been made, to date no suitable C3aR inhibitory drug candidate has emerged 
(Burns et al., 2013a). Despite these notes of caution, the results ultimately support the 
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